Details of the Drug

General Information of Drug (ID: DMD7L94)

Drug Name
Palbociclib
Synonyms
571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Schizophrenia 6A20 Terminated [3]
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01EF01: Palbociclib
L01EF: Cyclin-dependent kinase (CDK) inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 447.5
Logarithm of the Partition Coefficient (xlogp) 1.8
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 29.4 +/- 14.2 mcgh/L [4]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 9.6 mcg/L [4]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 0.5 h [4]
Bioavailability
The bioavailability of drug is 14-15% [4]
Clearance
The apparent oral clearance of drug is 63.1 L/h [5]
Elimination
The main route of elimination of palbociclib is through feces after hepatic metabolism while renal clearance seems to play a minor role accounting only for 17.5% of the eliminated dose [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 29 hours [5]
Metabolism
The drug is metabolized via the hepatic [5]
Vd
The volume of distribution (Vd) of drug is 2583 L [6]
Chemical Identifiers
Formula
C24H29N7O2
IUPAC Name
6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
Canonical SMILES
CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
InChI
InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
InChIKey
AHJRHEGDXFFMBM-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5330286
ChEBI ID
CHEBI:85993
CAS Number
571190-30-2
UNII
G9ZF61LE7G
DrugBank ID
DB09073
TTD ID
D00UZR
VARIDT ID
DR01288
INTEDE ID
DR1229
ACDINA ID
D00504
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 4 (CDK4) TT0PG8F CDK4_HUMAN Modulator [1]
Cyclin-dependent kinase 6 (CDK6) TTO0FDJ CDK6_HUMAN Modulator [1]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [7]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Protein Interaction/Cellular Processes [9]
Anillin (ANLN) OTXJY54C ANLN_HUMAN Gene/Protein Processing [10]
Apolipoprotein E (APOE) OTFOWL2H APOE_HUMAN Gene/Protein Processing [11]
Aurora kinase A (AURKA) OTMX0HYT AURKA_HUMAN Gene/Protein Processing [10]
Aurora kinase B (AURKB) OTIY4VHU AURKB_HUMAN Gene/Protein Processing [10]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Gene/Protein Processing [10]
Borealin (CDCA8) OT17D55D BOREA_HUMAN Gene/Protein Processing [10]
BRCA1-associated RING domain protein 1 (BARD1) OTTC0Z9Y BARD1_HUMAN Gene/Protein Processing [10]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Protein Interaction/Cellular Processes [10]
Cadherin-2 (CDH2) OTH0Y56P CADH2_HUMAN Gene/Protein Processing [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cyclin-dependent kinase 4 (CDK4) DTT CDK4 3.30E-72 0.65 2.39
P-glycoprotein 1 (ABCB1) DTP P-GP 3.12E-33 -8.30E-01 -1.04E+00
Breast cancer resistance protein (ABCG2) DTP BCRP 3.87E-47 -1.28E+00 -1.63E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 5.59E-39 -3.76E-01 -1.64E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC1; GDSC2 5.2991 13.1437 -0.0547 13.6032
ES1 GDSC1; GDSC2 -0.1094 7.079 -1.8467 36.5928
MHH-ES-1 GDSC1; GDSC2; CCLE 1.8305 6.4996 0.3668 19.4853
ES7 GDSC1; GDSC2 1.9529 9.1923 -0.8199 25.5198
CHSA0108 GDSC1; GDSC2 2.0943 17.0461 -5.4446 32.8346
ES8 GDSC1; GDSC2 2.3346 11.208 -1.4714 26.7523
EW-12 GDSC2 2.8934 8.3493 -0.4643 12.8776
ES5 GDSC1; GDSC2 2.951 11.1083 -1.7879 19.438
NOS-1 [Human HNSCC] GDSC1; GDSC2 3.099 5.6572 1.9637 8.1842
SK-ES-1 GDSC1; GDSC2; CCLE 3.1505 10.688 -0.5049 19.6905
U-CH2 GDSC2 3.3929 5.4783 1.2386 1.9753
EW-1 GDSC1; GDSC2 3.6482 7.8519 1.3228 10.3264
EW-16 GDSC1; GDSC2 3.6968 17.4431 -3.4287 28.7949
CHSA0011 GDSC1; GDSC2 3.8306 8.3688 0.1813 7.085
CADO-ES1 GDSC1; GDSC2 3.9759 8.6663 1.1732 10.3635
EW-24 GDSC1; GDSC2 4.1786 7.5003 1.8965 6.0151
EW-3 GDSC1; GDSC2 4.195 14.4343 -1.5245 22.0002
ES6 GDSC1; GDSC2 4.4024 15.2153 -1.75 22.3006
HuO9 GDSC1; GDSC2 4.4553 7.725 1.9782 5.0484
TC-71 GDSC1; GDSC2; CCLE 4.5529 9.6399 1.1208 8.879
SaOS-2 GDSC1; GDSC2; CCLE 4.6055 8.1223 1.8887 4.9526
EW-18 GDSC1; GDSC2 4.8741 7.9755 2.1262 3.5928
EW-7 GDSC1; GDSC2 4.8907 11.3361 0.5351 11.6605
EW-22 GDSC1; GDSC2 5.0389 10.5495 1.0196 8.9489
A-673 GDSC1; GDSC2; CCLE 5.1485 11.9936 0.3979 11.2076
SK-PN-DW GDSC1; GDSC2 5.1806 10.3572 1.2066 7.7398
CAL-72 GDSC1; GDSC2 5.4175 16.7521 -1.7368 20.0402
SW1353 CCLE 5.4308 7.2775 2.3945 0.3895
CAL-78 GDSC1; GDSC2; CCLE 5.572 7.9607 2.5019 1.0799
EW-13 GDSC1; GDSC2 5.689 8.6559 2.2738 1.9111
ES4 GDSC1; GDSC2 6.0282 15.3093 -0.5937 14.5012
CHSA8926 GDSC1; GDSC2 6.0494 14.1024 0.0003 11.9214
NY GDSC1; GDSC2 6.1116 8.706 2.4492 0.9413
U2OS GDSC1; GDSC2; CCLE 6.1687 14.1879 0.039 10.9869
EW-11 GDSC1; GDSC2 6.2218 20.3222 -2.8992 22.0885
HOS GDSC1; GDSC2; CCLE 6.2443 12.104 1.0612 6.3438
MG-63 GDSC1; GDSC2; CCLE 6.4359 17.19 -1.2198 15.5396
HuO-3N1 GDSC1; GDSC2 6.5078 8.6513 2.6273 0.3238
SJSA-1 GDSC1; GDSC2; CCLE 6.5555 17.9389 -1.4987 16.3303
G-292 clone A141B1 GDSC1; GDSC2 6.6459 17.8457 -1.3912 16.4382
H-EMC-SS GDSC1; GDSC2 6.7386 18.7018 -1.7403 17.5016
⏷ Show the Full List of 41 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 193 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JM1 GDSC1; GDSC2 2.624 7.6735 -0.335 12.8372
TALL-1 [Human adult T-ALL] GDSC2 -3.3199 -1.3105 -3.3253 53.356
697 GDSC1; GDSC2; CCLE -2.2077 2.5782 -2.5271 46.6713
MOLM-13 GDSC1; GDSC2 -1.9057 2.4313 -2.1669 46.7174
NB4 GDSC1; GDSC2 -1.8376 5.4335 -3.4487 42.7262
SIG-M5 GDSC2; CCLE -1.7571 -0.7319 -1.7571 40.855
JURL-MK1 GDSC1; GDSC2 -1.6115 6.9113 -3.8662 42.2618
RCH-ACV GDSC1; GDSC2 -1.5257 4.0958 -2.5701 39.1593
RPMI-8402 GDSC1; GDSC2; CCLE -1.4829 2.3989 -1.7017 40.8431
CTB-1 GDSC1; GDSC2 -1.2667 3.5855 -2.0958 36.2873
MV4-11 GDSC1; GDSC2 -0.9659 3.3836 -1.3745 39.3888
BC-1 GDSC1; GDSC2 -0.4851 7.6465 -2.4813 39.6707
HAL-01 GDSC1; GDSC2 -0.3938 3.2493 -0.7135 34.2532
KE-37 GDSC1; GDSC2 -0.272 4.8564 -1.105 35.1071
OCI-Ly7 GDSC1; GDSC2 -0.2683 4.1883 -1.2884 28.0653
RS4;11 GDSC1; GDSC2 -0.2206 5.6603 -1.363 35.7047
P12-Ichikawa GDSC1; GDSC2; CCLE -0.2203 5.2696 -1.2075 33.4278
SKM-1 GDSC1; GDSC2 -0.0335 6.0984 -1.9188 29.8472
Kasumi-1 GDSC2 0.1793 7.919 -2.5864 31.4659
SU-DHL-10 GDSC1; GDSC2; CCLE 0.2205 3.2885 -0.0537 27.1007
SU-DHL-5 GDSC1; GDSC2 0.2408 3.191 -0.0058 28.4144
SR GDSC1; GDSC2 0.2885 4.5599 -0.3933 29.914
MOLT-16 GDSC1; GDSC2; CCLE 0.3403 5.6535 -0.7701 29.6
RPMI-8866 GDSC1; GDSC2 0.4376 4.7186 -0.8099 22.6632
CMK-86 CCLE 0.5473 4.3277 -0.1281 24.1764
NKM-1 GDSC1; GDSC2 0.5586 7.1511 -1.1987 31.883
CML-T1 GDSC1; GDSC2 0.6138 4.5268 -0.032 26.985
HEL GDSC1; GDSC2 0.6149 6.2883 -1.3851 24.9133
MOLM-16 GDSC1; GDSC2 0.637 3.4908 -0.0525 17.574
GA-10 GDSC1; GDSC2 0.7975 6.0324 -0.4572 28.1206
Karpas-45 GDSC1; GDSC2 0.8242 5.6529 -0.2654 27.195
JVM-3 GDSC1; GDSC2; CCLE 0.8641 5.8009 -0.2878 25.6933
NU-DUL-1 GDSC1; GDSC2 0.8652 6.2098 -1.1121 22.6333
A3/Kawakami GDSC1; GDSC2 0.8761 5.8002 -0.2752 27.0371
KY821 GDSC1; GDSC2 0.8765 11.3094 -2.8564 35.2973
KMS-26 CCLE 0.8771 4.0587 0.3275 20.7969
KOPN-8 GDSC1; GDSC2 0.898 6.5566 -0.5875 28.273
JeKo-1 GDSC1; GDSC2 0.9163 7.154 -1.5278 24.4792
MOLT-13 GDSC1; GDSC2 0.9354 6.9865 -0.7451 28.762
KMS-34 CCLE 0.9516 4.9062 0.0603 21.8137
SU-DHL-6 GDSC1; GDSC2; CCLE 0.9591 8.2082 -1.29 29.2546
KO52 CCLE 0.9834 5.927 -0.3592 23.6659
BE-13 GDSC1; GDSC2 0.9946 5.6797 -0.1007 25.8074
NALM-6 GDSC1; GDSC2 1.047 5.7244 -0.0662 25.4524
CRO-AP2 GDSC1; GDSC2 1.0493 10.771 -3.201 30.361
WSU-NHL GDSC1; GDSC2 1.1193 6.9391 -0.5397 27.2484
MHH-PREB-1 GDSC1; GDSC2 1.1529 4.8442 0.4168 22.7672
OCI-Ly19 GDSC1; GDSC2 1.2018 7.3483 -1.3654 22.7078
KE-97 CCLE 1.2175 5.7862 -0.0602 21.47
L-363 GDSC1; GDSC2; CCLE 1.2379 4.8727 0.4944 20.8347
PL-21 GDSC1; GDSC2 1.3769 9.219 -2.1411 25.5658
GR-ST GDSC1; GDSC2 1.3992 8.3155 -0.9149 27.7406
CTV-1 GDSC1; GDSC2 1.4032 7.7459 -0.6391 26.637
JSC-1 GDSC1; GDSC2 1.4294 6.511 -0.0334 23.9059
Sc-1 GDSC1 1.4641 5.5433 -0.2359 19.2632
DB GDSC1; GDSC2 1.4756 6.4454 0.0427 23.3882
YT GDSC1; GDSC2 1.4969 5.0435 0.6929 20.1296
DEL GDSC1; GDSC2; CCLE 1.5208 5.8281 0.3707 20.4615
SUP-B8 GDSC1; GDSC2 1.5237 7.7665 -1.2892 21.2598
Mino CCLE 1.5422 5.3468 0.4659 17.8071
NK-92MI GDSC2 1.6349 4.3225 0.522 10.4715
Jurkat GDSC1; GDSC2; CCLE 1.6396 4.4378 1.0949 16.5735
LAMA-84 GDSC1; GDSC2 1.7477 7.4851 -0.1827 23.4905
BONNA-12 GDSC2 1.8178 6.0512 -0.1793 14.217
OCI-AML-3 GDSC1; GDSC2 1.8438 10.105 -1.3685 27.911
EM-2 GDSC1; GDSC2; CCLE 1.8605 6.862 0.2238 20.0686
KHM-1B CCLE 1.8793 7.2394 -0.1133 19.6036
WIL2 NS GDSC1; GDSC2 1.8942 6.2979 0.5242 19.6068
BDCM CCLE 1.9101 4.37 1.2801 12.4406
JVM-2 GDSC1; GDSC2 1.9124 8.1575 -0.3518 23.6976
BL-70 CCLE 1.9248 3.5738 1.6319 10.6136
MY-M12 GDSC1; GDSC2 1.9943 9.1177 -1.5637 21.1063
Jiyoye GDSC1; GDSC2 2.0066 12.3946 -2.3523 30.4673
BV-173 GDSC1; GDSC2 2.009 8.2498 -0.3066 23.1852
DoHH2 GDSC1; GDSC2; CCLE 2.0335 5.7275 0.7658 14.7219
OCI-AML-5 GDSC1; GDSC2; CCLE 2.0572 9.1522 -0.8933 22.5748
PF-382 GDSC1; GDSC2 2.0896 5.6887 1.0019 16.4906
WSU-DLCL2 GDSC1; GDSC2 2.1531 13.0608 -2.5529 30.5827
MJ CCLE 2.1629 6.5227 0.5002 15.7094
Farage GDSC1; GDSC2 2.1804 5.4537 0.4211 9.4681
Reh GDSC1; GDSC2; CCLE 2.2388 7.579 0.2348 18.8754
P32/ISH GDSC1; GDSC2 2.2493 5.2902 1.3455 14.1415
KCL-22 GDSC1; GDSC2; CCLE 2.264 5.3161 1.3479 13.2845
DG-75 GDSC1; GDSC2 2.2786 6.2672 0.9097 16.3678
RPMI-8226 GDSC1; GDSC2 2.3277 9.1517 -0.458 22.8451
ML-2 GDSC1; GDSC2 2.3503 8.7199 -0.2241 21.7442
Kasumi-2 CCLE 2.4094 6.1619 0.9034 12.8979
CCRF-CEM GDSC1; GDSC2 2.4101 7.5001 0.4316 18.4288
Mono-Mac-6 GDSC1; GDSC2 2.4211 4.3514 1.946 10.3669
MEC-1 CCLE 2.4218 6.0278 0.9808 12.4534
QIMR-WIL GDSC1; GDSC2 2.4808 9.5668 -1.3906 18.8654
Karpas-1106P GDSC1; GDSC2 2.4967 5.7702 1.3567 13.2927
SUP-M2 GDSC1; GDSC2; CCLE 2.5164 3.5182 2.3824 7.3331
P30/OHK GDSC1; GDSC2 2.53 6.082 1.2369 13.8393
OCI-AML-2 GDSC1; GDSC2; CCLE 2.5475 6.7048 0.9485 14.4824
A4/Fukuda GDSC1; GDSC2 2.5525 11.2111 -1.2809 25.4348
SU-DHL-16 GDSC1; GDSC2 2.5577 6.1523 0.3684 8.7919
Karpas-299 GDSC1; GDSC2; CCLE 2.6501 7.4848 0.6572 15.6584
SU-DHL-8 GDSC1; GDSC2; CCLE 2.6809 4.897 1.9523 8.9398
SU-DHL-4 GDSC1; GDSC2; CCLE 2.7072 4.6068 1.9411 6.5102
CMK GDSC1 2.7114 5.5272 0.7884 7.2483
Ci-1 CCLE 2.7575 3.5163 2.5197 3.2759
U-937 CCLE 2.7699 6.0655 1.2715 9.9485
KMM-1 CCLE 2.77 6.0045 1.302 9.7839
KMS-11 GDSC1; GDSC2; CCLE 2.7924 6.5459 1.0512 11.0694
Pfeiffer CCLE 2.8072 4.4965 2.0856 5.4562
KMS-12-BM GDSC2; CCLE 2.8339 11.71 -1.2854 23.587
CESS GDSC1; GDSC2 2.8718 4.236 2.4512 6.1611
Karpas-422 GDSC1; GDSC2; CCLE 2.879 10.7181 -0.7514 21.418
HH [Human lymphoma] GDSC1; GDSC2; CCLE 2.8937 7.7336 0.7498 14.5384
ALL-PO GDSC1; GDSC2 2.9012 6.4251 1.4071 11.819
P3HR-1 CCLE 2.913 5.0264 1.9134 6.1078
BALL-1 GDSC1; GDSC2 2.9394 11.8712 -1.2755 24.3159
JM-1 CCLE 2.9493 5.2286 1.8431 6.3957
NCO2 CCLE 2.9658 5.9044 1.5192 8.1076
EB1 CCLE 2.9942 6.0545 1.4679 8.3131
MC116 GDSC1; GDSC2; CCLE 2.9951 5.3685 1.8117 6.4509
BC-3 GDSC2 3.0002 5.0755 1.1943 2.822
SU-DHL-1 GDSC2 3.0156 18.4864 -5.4129 30.5814
Mono-Mac-1 CCLE 3.0509 5.122 1.9811 5.3954
ST486 GDSC1; GDSC2 3.0526 7.1715 1.1683 12.7018
OCI-M1 GDSC1; GDSC2 3.064 5.2329 2.1438 7.2787
BL-41 GDSC1; GDSC2; CCLE 3.0755 3.9688 2.7757 3.5381
Toledo CCLE 3.0815 5.329 1.9027 5.7462
MHH-CALL-4 GDSC2 3.0823 7.7572 -0.034 9.9336
Namalwa GDSC1; GDSC2 3.087 8.5539 0.5076 16.0873
NOMO-1 GDSC1; GDSC2 3.0871 8.0432 0.7628 14.7714
AMO1 GDSC1; GDSC2; CCLE 3.1062 4.9973 2.2983 5.9438
Ku812 GDSC1; GDSC2; CCLE 3.1107 10.6716 -0.5304 19.9003
Loucy GDSC1; GDSC2 3.1335 7.9485 0.8498 14.1881
GDM-1 GDSC1; GDSC2 3.1496 5.1387 2.2662 6.3593
KM-H2 GDSC1; GDSC2 3.1584 11.542 -0.9252 22.38
ATN-1 GDSC1; GDSC2 3.17 7.9013 0.9045 13.8005
Raji GDSC1; GDSC2; CCLE 3.1898 5.8873 1.9275 7.6781
RL GDSC1; GDSC2 3.2141 6.9949 0.4276 6.9038
ARH-77 GDSC1; GDSC2 3.2251 6.1618 1.8206 8.6416
HC-1 GDSC1; GDSC2 3.242 9.1236 0.3542 16.438
MLMA GDSC1; GDSC2 3.2482 9.3587 0.2418 16.9744
L-1236 GDSC1; GDSC2 3.2511 5.1803 2.3331 5.7119
THP-1 GDSC1; GDSC2 3.2724 7.4104 0.2677 7.7256
RPMI-6666 GDSC1; GDSC2 3.315 7.5805 1.1869 11.901
HuT 78 CCLE 3.3181 7.1608 1.1784 9.0911
MOLP-8 GDSC1; GDSC2; CCLE 3.3293 11.4674 -0.7447 20.2269
U-698-M GDSC1; GDSC2 3.3338 5.4287 2.2784 5.8025
HL-60 GDSC1; GDSC2 3.3356 10.3593 -0.1854 18.7569
CA46 GDSC1; GDSC2 3.3844 5.1675 2.4507 4.712
IM-9 GDSC1; GDSC2 3.4058 6.474 1.8153 8.2057
TUR GDSC1; GDSC2 3.4574 7.9213 1.1341 11.8212
EB2 GDSC1; GDSC2; CCLE 3.4615 5.0761 2.5583 3.7012
KMOE-2 GDSC1; GDSC2 3.4676 6.0274 2.0886 6.5287
LP-1 GDSC1; GDSC2; CCLE 3.6002 5.5698 2.1744 3.1824
EHEB GDSC1 3.6213 12.4768 -1.9563 21.3707
JJN-3 GDSC1; GDSC2 3.684 5.2292 2.6506 2.9189
MHH-CALL-2 GDSC1; GDSC2 3.6986 6.2592 2.1542 5.622
SCC-3 GDSC2 3.7428 9.2372 0.7073 13.3667
LC4-1 GDSC1; GDSC2 3.7673 11.3489 -0.3267 18.2774
VAL GDSC1; GDSC2 3.8006 11.13 -0.1908 17.585
K-562 GDSC1; GDSC2 3.8089 5.5461 2.5849 3.0251
OPM-2 GDSC1; GDSC2; CCLE 3.81 5.6103 2.5546 3.006
Hs 445 GDSC2 3.8132 5.6487 2.5382 3.2692
HT GDSC1; GDSC2; CCLE 3.819 6.7246 1.7682 4.8906
MOLT-4 GDSC1; GDSC2 3.9565 8.3195 1.3302 9.5638
MN-60 GDSC1; GDSC2 3.963 8.3656 1.3124 9.6455
L-428 GDSC1; GDSC2; CCLE 3.965 5.9603 2.4926 3.0392
KG-1 GDSC1; GDSC2; CCLE 4.0886 8.9285 1.1291 9.7771
RC-K8 GDSC1; GDSC2 4.128 7.7803 1.7236 7.0556
SUP-T1 GDSC1; GDSC2; CCLE 4.1916 8.4929 1.4206 8.0829
SUP-B15 GDSC1; GDSC2 4.1933 7.4569 1.9279 5.8161
HEL 92.1.7 CCLE 4.215 5.3388 2.6222 0.3906
DND-41 GDSC1; GDSC2 4.243 11.427 0.0091 15.601
NCI-H929 GDSC1; GDSC2 4.2489 8.1205 1.6445 7.2332
P31/FUJ GDSC1; GDSC2; CCLE 4.2979 7.0109 2.2136 3.8598
Granta-519 GDSC1; GDSC2; CCLE 4.5142 7.0666 2.3253 2.9726
HDLM-2 GDSC1; GDSC2 4.5253 9.8452 1.0007 10.0708
F-36P CCLE 4.5325 8.0703 1.5998 4.5105
ALL-SIL GDSC1; GDSC2; CCLE 4.6361 11.866 0.0895 13.6324
L-540 GDSC1; GDSC2 4.6798 9.4385 1.308 8.157
SUP-HD1 GDSC1; GDSC2 4.7616 8.6976 1.7184 5.8586
Daudi GDSC1; GDSC2 4.7775 7.4805 2.2939 2.9121
U266B1 GDSC1; GDSC2 4.7922 7.7926 2.1606 3.5464
SK-MM-2 GDSC1; GDSC2; CCLE 4.8022 10.4477 0.9046 9.4631
MEG-01 GDSC1; GDSC2; CCLE 4.8722 7.5504 2.3172 2.517
Karpas-231 GDSC1; GDSC2 4.9052 6.3814 2.8251 0.5389
ME1 GDSC1; GDSC2 4.9644 8.9289 1.7405 5.394
VL51 GDSC1; GDSC2 5.2375 7.566 2.5038 1.4261
Karpas-620 GDSC1; GDSC2; CCLE 5.2646 13.9918 -0.4934 14.8877
ROS-50 GDSC1; GDSC2 5.3202 12.7888 -0.9424 10.2224
EJM GDSC1; GDSC2 5.364 6.9062 2.8165 0.33
Ramos.2G6.4C10 GDSC1; GDSC2 5.3761 6.6857 2.8994 0.1656
EoL-1 GDSC1; GDSC2 5.4538 19.3393 -2.9869 23.8317
TK [Human B-cell lymphoma] GDSC1; GDSC2 5.4573 6.9389 2.8405 0.2466
MM1.S GDSC1; GDSC2 5.7784 10.877 1.3423 6.0683
H9 GDSC1; GDSC2 7.5493 19.8142 -1.723 16.0385
⏷ Show the Full List of 193 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCE-4 GDSC1; GDSC2 3.3781 9.6923 -0.7669 13.3442
TE-12 GDSC1; GDSC2 3.4387 9.6896 -0.7217 12.9594
KYAE-1 GDSC1; GDSC2 4.677 7.066 2.4222 2.4349
OACM5.1 C GDSC1; GDSC2 4.8508 11.1073 0.6182 11.3335
ESO-51 GDSC1; GDSC2 5.047 7.2044 2.5601 1.385
FLO-1 GDSC1; GDSC2 5.1142 19.2738 -3.214 25.1376
KYSE-50 GDSC1; GDSC2 5.1707 9.6373 1.5399 6.0672
KYSE-220 GDSC1; GDSC2 5.2731 7.5458 2.5294 1.2937
ESO-26 GDSC1; GDSC2 5.6857 7.5511 2.7076 0.4509
SK-GT-4 GDSC1; GDSC2 6.346 19.5559 -2.4336 20.4787
OACP4 C GDSC1; GDSC2 7.4245 18.2432 -1.0593 13.8699
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; GDSC2 4.1461 6.7145 2.2536 4.1582
Cancer Drug Sensitivity Data Curated from 35 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NB69 GDSC1; GDSC2 -1.3247 8.4763 -3.7066 45.0697
MHH-NB-11 GDSC1; GDSC2 -0.657 3.7343 -1.5059 30.8605
KP-N-SI9s CCLE 0.9452 6.542 -0.6799 25.2186
CHP-212 GDSC1; GDSC2 1.1409 12.5282 -3.2049 35.1884
SJNB-6 GDSC1; GDSC2 1.3111 9.5752 -2.376 26.701
SJNB-14 GDSC1; GDSC2 1.3319 10.423 -1.9983 31.591
CHP-126 GDSC1; GDSC2 1.3456 10.229 -2.6718 27.673
SK-N-BE(2) CCLE 1.7785 9.7573 -1.4438 25.5814
CHP-134 GDSC1; GDSC2 1.8507 7.3947 -0.0409 22.4973
IMR-32 CCLE 2.0653 6.9463 0.2024 17.5041
KP-N-YS GDSC1; GDSC2 2.2249 5.8467 0.2607 10.3411
SJNB-17 GDSC1; GDSC2 2.7315 6.6607 0.2476 9.0958
SJNB-10 GDSC1; GDSC2 2.7442 9.6649 -0.343 21.1032
LA-N-6 GDSC1; GDSC2 2.8715 13.21 -2.8963 24.0602
SJNB-5 GDSC1; GDSC2 3.3235 12.2756 -2.0808 19.7528
SK-N-DZ GDSC1; GDSC2; CCLE 3.4694 9.6832 0.2633 15.4498
SiMa GDSC1; GDSC2; CCLE 3.5643 13.7378 -1.6854 23.1459
SK-N-MC-IXC GDSC1; GDSC2 3.5762 5.0984 1.4851 0.6802
IMR-5 GDSC1; GDSC2 3.8461 8.4254 1.1928 10.5588
SK-N-AS GDSC1; GDSC2; CCLE 4.1602 12.3545 -0.5162 17.3067
SK-N-SH GDSC1; GDSC2; CCLE 4.4473 13.7955 -1.0091 18.6507
SJNB-7 GDSC1; GDSC2 4.5773 8.7901 1.5501 7.0836
KP-N-YN GDSC1; GDSC2 4.6732 8.457 1.7744 5.7251
Kelly GDSC1; GDSC2 4.7172 11.7519 0.2057 13.6135
KP-N-RT-BM-1 GDSC2 4.7411 6.9455 1.2725 0.6347
GI-ME-N GDSC1; GDSC2 4.9237 17.2247 -2.3438 23.0616
NB(TU)1 GDSC1; GDSC2 4.9768 12.5717 -0.0068 14.0498
SK-N-BE(2)-M17 GDSC1; GDSC2 5.1195 16.7711 -1.9696 21.4498
SJNB-13 GDSC1; GDSC2 5.2102 11.0664 0.8879 9.2869
TGW GDSC1; GDSC2 5.226 7.1446 2.6687 0.8281
NH-12 GDSC1; GDSC2 5.2976 16.1649 -1.5366 19.5882
NB1 GDSC1; GDSC2 5.4918 15.5799 -1.1062 17.5945
GOTO GDSC1; GDSC2 5.5539 10.7216 1.2755 6.7524
SK-N-FI GDSC1; GDSC2 5.8846 18.6755 -2.3379 21.0675
SJNB-12 GDSC1; GDSC2 8.6091 20.0843 -1.1699 12.4445
⏷ Show the Full List of 35 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC1; GDSC2; CCLE 4.699 10.6565 0.7293 10.5105
Cancer Drug Sensitivity Data Curated from 55 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCC1954 GDSC1; GDSC2; CCLE 2.9605 4.9196 2.205 6.827
HCC1569 GDSC1; GDSC2; CCLE 3.3512 5.1643 2.1948 3.5634
Evsa-T GDSC1; GDSC2 3.5323 5.0967 2.6031 3.4986
HCC1599 GDSC2 3.6839 6.4592 0.968 2.965
HCC1806 GDSC1; GDSC2; CCLE 3.7639 5.5886 2.5325 3.2066
HDQ-P1 GDSC1; GDSC2; CCLE 3.8057 5.6295 2.5422 3.0771
BT-549 GDSC1; GDSC2; CCLE 3.8663 5.4049 2.6917 2.2129
DU4475 GDSC1; GDSC2 4.1303 6.1197 2.5257 2.7448
MDA-MB-330 GDSC1; GDSC2 4.1414 8.2363 0.434 5.1037
HCC2218 GDSC1; GDSC2 4.177 13.0333 -1.8244 16.587
CAL-148 GDSC2 4.2812 7.01 2.203 4.1652
CAL-51 GDSC1; GDSC2 4.311 9.4074 1.059 10.1929
YMB-1-E GDSC2 4.3172 6.6145 1.2198 1.0857
AU565 GDSC1; GDSC2; CCLE 4.3309 10.2222 0.6724 11.5331
HCC202 GDSC1; GDSC2 4.3577 6.2195 1.3868 0.5088
MCF-7 GDSC1; GDSC2; CCLE 4.4308 10.6216 0.55 11.9145
COLO 824 GDSC1; GDSC2 4.5557 6.7466 2.4957 2.2436
HCC1187 GDSC1; GDSC2; CCLE 4.5773 8.2568 1.806 5.4107
MDA-MB-468 GDSC1; GDSC2; CCLE 4.8133 7.0547 2.503 1.7773
Hs 739.T CCLE 4.8164 10.3864 0.6889 8.5518
UACC-893 GDSC2 4.8224 12.8421 -1.2877 12.7781
MDA-MB-453 GDSC1; GDSC2; CCLE 4.8349 11.1373 0.5921 10.9007
MRK-nu-1 GDSC1; GDSC2 4.9356 10.5396 0.9534 9.456
MDA-MB-231 GDSC1; GDSC2 4.997 13.246 -0.3227 15.3809
BT-483 GDSC1; GDSC2 5.02 6.9286 2.6604 1.0158
BT-474 GDSC1; GDSC2; CCLE 5.046 8.9351 1.7889 4.7319
HMC-1-8 CCLE 5.0866 11.405 0.3835 9.5414
MDA-MB-436 GDSC1; GDSC2; CCLE 5.1206 7.6771 2.3976 1.8787
CAL-85-1 GDSC1; GDSC2; CCLE 5.1292 9.1103 1.7594 4.7462
CAL-120 GDSC1; GDSC2 5.2533 12.7148 0.1215 12.8579
UACC-812 GDSC2; CCLE 5.3035 12.4808 0.2703 11.4999
MDA-MB-415 GDSC1; GDSC2; CCLE 5.3642 11.0053 1.0199 7.9008
Hs 578T GDSC1; GDSC2; CCLE 5.3659 13.5743 -0.2168 13.5279
EFM-19 GDSC1; GDSC2; CCLE 5.3909 12.4129 0.3638 10.9141
JIMT-1 GDSC1; GDSC2 5.4401 7.2511 2.7197 0.5369
HCC38 GDSC1; GDSC2 5.4728 7.7836 2.527 1.1301
EFM-192A GDSC1; GDSC2 5.4939 7.5999 2.6091 0.8354
HCC2157 GDSC1; GDSC2 5.4962 7.0841 2.8034 0.3076
HCC1428 GDSC1; GDSC2 5.5326 10.7202 1.2628 6.8305
HCC1419 GDSC1; GDSC2 5.598 8.3545 2.3541 1.6727
OCUB-M GDSC1; GDSC2 5.657 7.7219 2.6321 0.6646
ZR-75-30 GDSC1; GDSC2; CCLE 5.7739 7.5477 2.7432 0.316
HCC70 GDSC1; GDSC2; CCLE 5.7942 7.5441 2.7522 0.2921
MDA-MB-157 GDSC1; GDSC2; CCLE 5.8009 7.9568 2.6034 0.6306
BT-20 GDSC1; GDSC2; CCLE 5.8018 7.5372 2.7575 0.2798
HCC1937 GDSC1; GDSC2 5.879 7.8976 2.6572 0.4868
HCC1500 GDSC1; GDSC2 5.885 7.3916 2.8385 0.1425
SK-BR-3 CCLE 5.9885 7.6771 2.4595 0.1337
MDA-MB-361 GDSC1; GDSC2 6.0352 16.9863 -1.4023 17.5831
MDA-MB-175-VII GDSC1; GDSC2; CCLE 6.2788 13.2819 0.5376 8.6303
HCC1143 GDSC1; GDSC2 6.6689 14.7552 0.0957 10.4029
CAMA-1 GDSC1; GDSC2; CCLE 6.7501 14.4665 0.2816 9.0197
MFM-223 GDSC1; GDSC2 6.8805 17.0647 -0.858 13.9871
T-47D GDSC1; GDSC2; CCLE 7.1501 18.1058 -1.1746 14.1663
HCC1395 GDSC1; GDSC2 7.6792 17.2888 -0.4505 11.0827
⏷ Show the Full List of 55 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 58 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
D283 Med GDSC1; GDSC2 0.4863 10.2575 -2.7213 36.3515
D-247MG GDSC1; GDSC2 2.1036 14.3905 -4.1091 29.7993
D-423MG GDSC1; GDSC2 2.4117 10.5902 -1.957 21.6508
YKG-1 GDSC1; GDSC2; CCLE 2.6865 6.6207 0.9222 12.0365
D-566MG GDSC1; GDSC2 2.7937 8.0509 -0.3922 12.7233
NMC-G1 GDSC1; GDSC2 2.8594 6.8389 0.254 8.7465
D-502MG GDSC1; GDSC2 3.0986 13.7399 -2.9814 23.7741
KNS-81 CCLE 3.1511 8.317 0.4663 13.2243
H4 GDSC1; GDSC2; CCLE 3.2094 10.4964 -0.3595 18.9191
KNS-60 CCLE 3.2837 10.6232 -0.5778 17.8962
KNS-81-FD GDSC1; GDSC2 3.3046 6.9602 0.5047 6.2596
LN-229 GDSC1; GDSC2; CCLE 3.4646 6.4681 1.8661 7.3362
Onda 10 GDSC1; GDSC2 3.4736 6.0344 1.0382 2.9086
MOG-G-UVW GDSC1; GDSC2 3.5213 12.539 -1.1215 22.1823
LN-18 GDSC1; GDSC2; CCLE 3.5458 10.5232 -0.0939 16.9109
GMS-10 CCLE 3.6871 6.9217 1.5781 6.1511
GB-1 GDSC1; GDSC2; CCLE 3.8521 6.5492 2.126 5.1321
LNZTA3WT4 GDSC1; GDSC2 3.8667 13.0721 -2.0679 18.3857
8-MG-BA GDSC1; GDSC2 3.8934 7.0588 1.9057 6.5617
SF126 GDSC1; GDSC2; CCLE 4.0958 9.0853 0.8152 9.3033
KALS-1 GDSC2; CCLE 4.1512 8.3521 1.46 7.9634
D-245MG GDSC2 4.1661 9.5572 -0.1619 8.3483
D-542MG GDSC1; GDSC2 4.2169 5.9309 1.4369 0.4437
A-172 GDSC2; CCLE 4.2561 10.3309 0.5623 12.2238
D-336MG GDSC2 4.3245 7.7796 0.7403 3.235
D-263MG GDSC1; GDSC2 4.4057 13.1166 -0.7041 18.3554
SNB-75 GDSC1; GDSC2 4.466 6.356 1.3797 0.4775
ONS-76 GDSC1; GDSC2; CCLE 4.5356 12.2394 -0.1702 15.0004
Onda 11 GDSC1; GDSC2 4.6571 6.7031 1.3281 0.5236
U-87MG ATCC GDSC1; GDSC2; CCLE 4.8802 11.0852 0.6498 10.5389
CAS-1 GDSC1; GDSC2; CCLE 4.9439 10.6052 0.9274 9.0874
M059J GDSC1; GDSC2; CCLE 4.9757 6.6984 2.7323 0.7502
SF539 GDSC1; GDSC2 5.06 8.4435 2.0237 3.8205
SF295 GDSC1; GDSC2; CCLE 5.0955 13.8897 -0.8126 14.8994
PFSK-1 GDSC1; GDSC2 5.1479 9.5698 1.5571 6.0187
KS-1 [Human Krukenberg tumour] GDSC1; GDSC2 5.3385 14.4349 -0.6568 16.122
LN-405 GDSC1; GDSC2 5.3911 7.0571 2.772 0.4249
GI-1 GDSC1; GDSC2 5.4052 7.032 2.7869 0.3821
Daoy GDSC1; GDSC2; CCLE 5.4557 7.1755 2.7542 0.4148
MOG-G-CCM GDSC1; GDSC2; CCLE 5.4957 10.7981 1.203 6.8182
KNS-42 GDSC1; GDSC2; CCLE 5.5928 15.8181 -1.3978 16.2677
SW1783 GDSC1; GDSC2 5.6351 7.8373 2.5786 0.8419
Becker GDSC1; GDSC2 5.719 16.5855 -1.4338 18.3561
T98G GDSC1; GDSC2; CCLE 5.7374 11.341 1.1021 6.9101
DK-MG GDSC1; GDSC2; CCLE 5.797 16.6067 -1.3877 17.3158
SF268 GDSC1; GDSC2 5.839 16.2786 -1.1973 17.2447
42-MG-BA GDSC1; GDSC2 5.9424 7.823 2.7089 0.3469
DBTRG-05MG GDSC1; GDSC2; CCLE 6.0007 13.2404 0.3781 9.7868
AM-38 GDSC1; GDSC2 6.179 16.7662 -1.1937 16.5742
KINGS-1 GDSC1; GDSC2 6.241 16.9637 -1.246 16.6527
Hs 683 GDSC1; GDSC2; CCLE 6.3812 18.6601 -2.2226 17.755
U-118MG GDSC1; GDSC2; CCLE 6.5202 14.2804 0.2236 9.622
U-251MG GDSC1; GDSC2 6.6494 17.2084 -1.0821 15.2866
SK-MG-1 GDSC1; GDSC2 7.1005 19.5789 -1.9138 17.4465
GaMG GDSC1; GDSC2 7.181 19.2155 -1.6843 16.5287
D-392MG GDSC1; GDSC2 7.1877 17.755 -0.983 13.9757
YH-13 GDSC1; GDSC2 8.1682 27.5283 -5.0187 23.9541
SW1088 GDSC1; GDSC2; CCLE 8.3149 21.5478 -2.0414 15.3036
⏷ Show the Full List of 58 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ETK-1 GDSC1; GDSC2 3.8094 12.3783 -0.8067 20.2099
TGBC1TKB GDSC1; GDSC2 6.0888 13.0345 0.5325 9.43
TGBC24TKB GDSC1; GDSC2 7.0175 16.0227 -0.2762 11.4436
Cancer Drug Sensitivity Data Curated from 17 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEC-1-B CCLE 2.2493 5.5573 1.0522 12.5747
HEC-59 CCLE 3.3229 4.7629 2.371 2.6838
HEC-6 CCLE 3.7409 8.8424 0.671 10.7964
HEC-265 CCLE 3.8174 5.6487 2.2791 2.2796
HEC-1-A CCLE 4.1265 8.0215 1.3548 6.46
HEC-151 CCLE 4.2092 8.0622 1.3919 6.1147
EN GDSC1; GDSC2; CCLE 4.6297 6.7352 2.5425 1.8218
RL95-2 GDSC1; GDSC2; CCLE 4.8574 10.8972 0.7251 10.2234
HEC-251 CCLE 4.9439 6.6352 2.4362 0.509
ESS-1 GDSC1; GDSC2 4.9954 8.8708 1.7873 5.1042
MFE-319 GDSC2 5.0076 7.7085 2.323 2.463
TEN CCLE 5.1145 6.878 2.4154 0.4776
AN3-CA GDSC1; GDSC2; CCLE 5.123 11.1857 0.771 9.5081
KLE GDSC1; GDSC2; CCLE 5.2272 7.5461 2.507 1.3427
EFE-184 CCLE 5.3064 7.232 2.3615 0.523
MFE-280 GDSC1; GDSC2; CCLE 5.5575 7.7686 2.5713 0.8659
MFE-296 GDSC1; GDSC2 5.7804 8.4482 2.4027 1.3337
⏷ Show the Full List of 17 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 35 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KTCTL-140 GDSC1; GDSC2 0.1429 6.3452 -1.8639 28.9
LB2241-RCC GDSC1; GDSC2 0.3033 6.9374 -1.9941 28.7971
BB65-RCC GDSC1; GDSC2 1.1479 7.1661 -1.3235 22.6888
RXF 393L GDSC1; GDSC2 1.2449 8.5121 -1.9049 25.0219
LB1047-RCC GDSC1; GDSC2 1.2824 7.3463 -1.2924 22.0763
CAL-54 GDSC1; GDSC2 1.8544 9.3999 -1.0126 26.5841
NCC010 GDSC1; GDSC2 2.3743 9.8831 -1.6341 20.3187
769-P GDSC1; GDSC2; CCLE 2.5044 9.5615 -0.5029 21.4167
KTCTL-26A GDSC1; GDSC2 2.5075 10.8983 -2.0336 21.7088
KTCTL-13 GDSC1; GDSC2 2.559 5.183 0.8469 5.8257
ACHN GDSC2 2.6263 10.9019 -1.0623 24.4069
HA7-RCC GDSC1; GDSC2 2.714 11.6913 -2.2642 22.0944
KTCTL-21 GDSC1; GDSC2 2.8015 9.6828 -1.1956 17.025
UO-31 GDSC2 2.9788 6.1228 0.6862 5.8592
KTCTL-1M GDSC1; GDSC2 3.0633 11.2493 -1.7711 19.0702
SW156 GDSC2 3.1383 12.6167 -2.3921 21.4898
Caki-1 GDSC1; GDSC2 3.2335 11.5544 -1.7922 18.7291
NCC021 GDSC1; GDSC2 3.3144 8.5229 -0.2415 10.5928
A-704 GDSC1; GDSC2 3.4374 7.7103 1.2232 11.39
BFTC-909 GDSC1; GDSC2; CCLE 3.7067 11.9397 -0.6707 19.0005
A-498 GDSC1; GDSC2 3.8826 7.9076 1.478 8.93
786-O GDSC1; GDSC2; CCLE 4.4075 11.3808 0.1575 13.8038
Caki-2 CCLE 4.8274 6.2993 2.5141 0.3643
KMRC-2 CCLE 5.1869 7.2588 2.3011 0.7597
TK-10 GDSC1; GDSC2 5.1903 13.8241 -0.4651 15.626
KMRC-1 GDSC1; GDSC2; CCLE 5.2058 12.8441 0.0249 12.7838
VMRC-RCW GDSC2; CCLE 5.2408 6.8232 2.485 0.2695
VMRC-RCZ GDSC1; GDSC2; CCLE 5.3091 10.4765 1.2342 6.9719
KTCTL-195 GDSC1; GDSC2 5.3978 13.9555 -0.3798 14.8346
SN12C GDSC1; GDSC2 5.4944 13.134 0.0872 12.5728
LB996-RCC GDSC1; GDSC2 5.5787 13.4198 0.0076 12.7703
RCC10RGB GDSC1; GDSC2 5.7328 15.9058 -1.0915 17.0527
SW13 GDSC2 5.7824 15.1092 -0.6684 15.2796
OS-RC-2 GDSC1; GDSC2 6.9981 17.0264 -0.7621 13.4418
KMRC-20 GDSC1; GDSC2 8.7931 19.6166 -0.8434 10.9944
⏷ Show the Full List of 35 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 54 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO201 CCLE 0.8957 4.9571 -0.0195 22.393
KM12 GDSC1; GDSC2 1.0395 6.582 -0.4561 27.1185
NCI-H508 GDSC1; GDSC2 1.8318 10.3868 -2.3344 24.8401
COLO 320HSR GDSC1; GDSC2 2.3952 3.7501 2.1682 9.2794
LoVo GDSC1; GDSC2 2.4928 9.3509 -0.4086 22.073
LS513 GDSC1; GDSC2; CCLE 2.7038 11.6797 -1.5891 23.4972
COLO 320 CCLE 2.722 5.9333 1.2957 9.9452
SNU-175 GDSC2 2.821 13.7589 -2.3197 28.0077
LS180 GDSC1; GDSC2 2.8472 9.6819 -0.2619 20.3925
HT115 GDSC1; GDSC2 2.8868 8.93 -0.7565 14.4655
HCT 116 GDSC1; GDSC2; CCLE 3.1293 7.9447 0.8481 13.4329
SW48 GDSC1; GDSC2; CCLE 3.2153 10.9271 -0.5699 20.7182
SK-CO-1 GDSC1; GDSC2; CCLE 3.4586 9.9543 0.1189 16.1522
SNU-1040 GDSC2 3.5046 8.618 -0.1545 9.6382
SW948 GDSC1; GDSC2 3.6178 6.8507 1.7976 7.7621
LS1034 GDSC1; GDSC2 3.6324 5.4496 2.5045 3.8201
COLO205 GDSC1; GDSC2; CCLE 3.6334 9.7294 0.3739 14.5306
NCI-H716 GDSC1; GDSC2 3.6759 14.0318 -1.7409 23.9643
HCT 15 GDSC1; GDSC2; CCLE 3.683 8.6509 0.9521 11.5676
SNU-283 GDSC2 3.7961 5.4188 1.4563 0.6242
SW1463 GDSC1; GDSC2 3.8688 12.5227 -0.831 20.1131
HCC-56 CCLE 3.9194 6.9673 1.7205 4.9506
C2BBe1 GDSC1; GDSC2; CCLE 3.9238 7.621 1.651 7.4482
LS411N GDSC1; GDSC2 3.9967 11.2899 -0.1146 16.7129
SNU-C2A CCLE 4.1049 8.4634 1.1253 7.6888
SNU-81 GDSC1; GDSC2 4.1193 10.5948 -0.6853 11.2185
NCI-H747 GDSC1; GDSC2; CCLE 4.1536 11.0596 0.1224 14.5169
SW620 GDSC1; GDSC2; CCLE 4.5062 12.8412 -0.4904 16.4356
SNU-C1 GDSC1; GDSC2 4.522 7.3113 2.2166 3.6799
SNU-C5 GDSC1; GDSC2 4.5686 10.5001 0.7114 11.426
SW403 CCLE 4.5805 13.0286 -0.7659 15.7516
HT-55 GDSC1; GDSC2 4.6625 11.3689 0.3537 12.9883
SNU-61 GDSC1; GDSC2 4.694 7.8993 2.0506 4.2577
SW480 CCLE 4.757 8.1327 1.708 3.6476
LS123 GDSC1; GDSC2; CCLE 4.7735 7.3205 2.3636 2.4356
DiFi GDSC1; GDSC2 5.0051 12.3743 0.1103 13.4159
HT-29 GDSC1; GDSC2; CCLE 5.028 15.0096 -1.1682 18.0246
T84 GDSC1; GDSC2; CCLE 5.0696 7.174 2.5838 1.1967
SNU-407 GDSC1; GDSC2 5.2454 10.8845 0.9985 8.644
CCK-81 GDSC1; GDSC2 5.3039 11.4137 0.7848 9.5947
SW837 GDSC2 5.438 11.4762 0.8448 9.0536
GP5d GDSC1; GDSC2 5.516 11.3486 0.9567 8.366
HCC2998 GDSC1; GDSC2 5.5554 12.0399 0.6544 9.7653
CW-2 GDSC1; GDSC2 5.5985 11.1166 1.1192 7.4274
SW1116 GDSC1; GDSC2 5.6431 7.0934 2.8547 0.1706
RKO GDSC1; GDSC2; CCLE 5.7474 14.0503 -0.1801 12.6606
SW1417 GDSC1; GDSC2; CCLE 5.8761 12.9296 0.4436 9.7028
SNU-C2B GDSC1; GDSC2; CCLE 5.9861 11.6133 1.1301 6.4056
MDST8 GDSC1; GDSC2 6.1041 16.0903 -0.9185 15.6264
CaR-1 GDSC1; GDSC2 6.2799 15.8823 -0.6968 14.4185
CL-11 GDSC1; GDSC2 6.6728 15.6385 -0.3177 12.164
SW626 GDSC1; GDSC2 7.1416 16.7292 -0.5284 12.2725
RCM-1 [Human ESC] GDSC1; GDSC2 7.6209 18.6187 -1.1091 13.7064
COLO 678 GDSC1; GDSC2; CCLE 7.7619 16.4085 0.0041 8.7152
⏷ Show the Full List of 54 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1; GDSC2 4.0987 9.477 0.8654 11.7064
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Hep-G2 CCLE 3.1507 7.9652 0.6419 12.3214
PLC/PRF/5 CCLE 3.5026 7.452 1.1778 8.6742
HuH-1 GDSC1; GDSC2; CCLE 3.7468 11.136 -0.2369 17.0646
SNU-182 CCLE 3.7854 7.6077 1.3134 7.3489
SK-HEP-1 GDSC1; GDSC2; CCLE 3.989 10.2915 0.3763 13.6988
HLF CCLE 4.1272 6.0176 2.2948 1.7649
Hep-G2/C3A GDSC1; GDSC2; CCLE 4.4197 9.5529 1.0672 9.4075
SNU-423 GDSC1; GDSC2; CCLE 4.5393 10.2044 0.8349 10.3145
JHH-6 GDSC1; GDSC2; CCLE 4.5419 10.0705 0.9024 9.9788
Hep 3B2.1-7 GDSC1; GDSC2; CCLE 4.5982 6.3058 2.4131 0.8035
JHH-1 GDSC1; GDSC2 4.9105 5.9948 2.9701 0.1715
JHH-7 GDSC1; GDSC2 5.1844 8.2049 2.2023 2.7944
HLE GDSC1; GDSC2; CCLE 5.1873 9.9309 1.4126 6.3156
SNU-398 GDSC1; GDSC2 5.9112 15.7046 -0.8668 15.8273
SNU-449 GDSC1; GDSC2; CCLE 6.104 13.5052 0.3203 9.8716
JHH-2 GDSC1; GDSC2; CCLE 6.2867 12.7911 0.7709 7.5806
JHH-4 GDSC1; GDSC2; CCLE 7.0167 14.8314 0.2772 8.6435
SNU-387 GDSC1; GDSC2 7.1139 19.1973 -1.7211 16.7714
Huh-7 GDSC1; GDSC2 7.7859 21.1338 -2.1946 17.2026
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 204 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H290 GDSC1; GDSC2 0.261 7.5857 -2.3477 30.316
NCI-H2804 GDSC1; GDSC2 0.3555 7.7031 -2.316 29.8387
COLO 677 CCLE 0.4656 2.9946 0.2356 22.7994
NCI-H838 GDSC1; GDSC2 0.9739 11.9007 -3.8294 32.3525
NCI-H2286 CCLE 1.1211 5.8507 -0.1862 22.3927
Lu-99 CCLE 1.4335 5.1546 0.4446 18.2735
ABC-1 GDSC1; GDSC2 1.6428 10.4024 -2.5024 26.1219
NCI-H520 GDSC1; GDSC2; CCLE 1.6565 13.2315 -3.0811 32.1957
NCI-H292 GDSC1; GDSC2 2.2894 4.4134 1.0252 5.3797
BEN GDSC1; GDSC2 2.4327 10.5059 -1.8979 21.3359
NCI-H209 GDSC1; GDSC2 2.4462 5.9307 1.2312 14.1278
NCI-H460 GDSC1; GDSC2 2.4787 11.246 -2.2304 22.604
NCI-H2122 GDSC1; GDSC2; CCLE 2.7654 7.9731 0.5178 16.0307
NCI-H146 GDSC1; GDSC2 2.7671 5.0314 1.0661 4.0189
COLO 699 CCLE 2.7937 7.8134 0.4193 14.3746
NCI-H1437 GDSC1; GDSC2 2.8186 9.3492 -1.0166 16.0663
NCI-H69 GDSC1; GDSC2 2.8507 3.7078 2.668 5.0782
NCI-H2444 GDSC1; GDSC2; CCLE 2.9114 5.8507 1.5002 8.3479
NCI-H345 GDSC1; GDSC2 2.971 3.7139 1.7562 0.1869
EMC-BAC-1 GDSC1; GDSC2 3.0173 9.2158 -0.7992 14.4049
A-427 GDSC1; GDSC2 3.0296 8.7879 -0.5788 13.174
Hs 229.T CCLE 3.0638 6.6583 1.2238 9.4559
NCI-H2172 GDSC1; GDSC2; CCLE 3.2057 4.1497 2.5863 1.7788
NCI-H1944 GDSC1; GDSC2; CCLE 3.2198 7.6706 1.0619 12.1179
NCI-H3122 GDSC1; GDSC2 3.2388 13.6493 -1.9112 25.6961
NCI-H835 GDSC1; GDSC2 3.2462 6.31 1.7643 8.8994
NCI-H524 GDSC1; GDSC2 3.3271 4.7767 2.5988 4.0288
NCI-H847 GDSC1; GDSC2 3.3804 4.83 2.6161 3.7981
SHP-77 GDSC1; GDSC2; CCLE 3.3819 6.7446 1.6603 8.6125
LC-1/sq-SF CCLE 3.4275 5.0537 2.304 2.8312
ChaGo-K-1 GDSC1; GDSC2 3.4342 6.4955 0.8053 4.2667
LC-2/ad GDSC1; GDSC2 3.4426 8.8739 -0.3215 10.7524
SBC-1 GDSC1; GDSC2 3.4656 5.0381 1.4592 0.8716
HARA [Human squamous cell lung carcinoma] GDSC1; GDSC2 3.509 18.8004 -4.262 31.0709
DMS 114 GDSC1; GDSC2; CCLE 3.5481 8.6637 0.8371 12.4616
NCI-H2803 GDSC2 3.5839 8.3976 0.0055 8.5849
IST-SL2 GDSC1; GDSC2 3.5976 6.1473 2.1319 5.9768
NCI-H2110 GDSC1; GDSC2 3.6007 6.6017 0.8566 3.6958
CAL-12T GDSC1; GDSC2 3.6115 10.4089 -0.9488 13.7469
NCI-H82 GDSC1; GDSC2 3.6268 5.399 2.5252 3.7296
NCI-H2795 GDSC1; GDSC2 3.636 13.3679 -1.4418 23.0739
COR-L32 GDSC2 3.636 5.6792 2.3937 4.4362
NCI-H64 GDSC1; GDSC2 3.6644 5.3119 2.5959 3.2592
NCI-H510A GDSC1; GDSC2 3.6843 7.6206 0.4386 5.9008
NCI-H647 GDSC1; GDSC2; CCLE 3.6909 7.8906 1.1039 8.6525
LB647-SCLC GDSC1; GDSC2 3.6944 5.2524 1.4767 0.6241
NCI-H1734 GDSC2 3.7238 5.625 1.3432 1.1101
Lu-134-A GDSC1; GDSC2 3.7255 8.7103 -0.049 8.5996
NCI-H1770 GDSC1; GDSC2 3.7524 6.9361 0.7942 3.7921
Lu-139 GDSC1; GDSC2 3.8121 11.2968 -1.2384 14.7365
NCI-H1304 GDSC1 3.8186 5.1886 1.5512 0.4108
CPC-N GDSC1; GDSC2 3.8299 7.6014 1.5894 8.4411
NCI-H211 GDSC1; GDSC2; CCLE 3.8416 13.0627 -1.1224 20.46
HCC4006 CCLE 3.8528 8.2056 1.0692 8.4911
SBC-3 GDSC1; GDSC2 3.8882 12.2049 -0.657 19.3975
SW900 CCLE 3.8917 6.5025 1.9246 3.9461
Lu-65 GDSC1; GDSC2 3.9246 6.6466 2.1312 5.2588
Lu-135 GDSC1; GDSC2 3.9696 6.0473 2.4539 3.4201
NCI-H1339 CCLE 3.9774 7.4544 1.5254 5.8565
NCI-H2228 GDSC1; GDSC2; CCLE 4.0066 7.3333 1.8543 6.2274
DMS 79 GDSC1; GDSC2 4.0092 5.9413 1.3468 0.8555
Calu-1 CCLE 4.0355 5.9989 2.2503 2.0951
NCI-H446 GDSC1; GDSC2 4.0375 5.8496 2.5931 2.5618
NCI-H322M GDSC1; GDSC2 4.0388 12.051 -0.4606 18.1947
LUDLU-1 CCLE 4.0585 7.8347 1.3979 6.3654
NCI-H2869 GDSC1; GDSC2 4.0612 10.0112 -0.4454 10.0978
SK-LU-1 GDSC1; GDSC2; CCLE 4.0758 11.0894 0.0472 15.0346
NCI-H187 GDSC1 4.0874 5.1387 1.6653 0.0757
NCI-H2029 GDSC1; GDSC2 4.0927 5.5667 1.5203 0.291
HCC44 GDSC1; GDSC2 4.1013 7.2759 1.9508 5.8775
GLC-82 CCLE 4.122 7.2637 1.7151 4.6142
LCLC-103H GDSC1; GDSC2; CCLE 4.1298 9.4607 0.897 10.854
NCI-H2196 GDSC2 4.1302 5.9454 1.3966 0.6063
EPLC-272H GDSC1; GDSC2 4.1316 8.8932 1.1789 9.9826
NCI-H1993 GDSC1; GDSC2 4.1338 10.1627 0.5523 13.2251
COR-L303 GDSC2 4.1348 5.8658 1.4281 0.5094
NCI-H2171 GDSC2 4.1374 5.472 1.57 0.178
EBC-1 GDSC1; GDSC2; CCLE 4.1382 12.7069 -0.7089 18.1512
COR-L279 GDSC1; GDSC2 4.1463 6.4262 2.3914 3.4273
A-549 GDSC1; GDSC2; CCLE 4.1517 13.3792 -1.033 19.4017
COR-L321 GDSC1; GDSC2 4.1579 5.6557 1.5132 0.2827
NCI-H2030 GDSC2; CCLE 4.1641 7.816 1.4795 5.7469
COR-L311 GDSC2 4.1669 6.0535 2.5796 2.416
NCI-H720 GDSC1; GDSC2 4.2231 6.0343 2.6229 2.1106
COLO 668 GDSC1; GDSC2 4.2293 6.5234 2.3995 3.2393
NCI-H250 GDSC2 4.2389 6.0442 1.404 0.5235
NCI-H2135 GDSC1; GDSC2 4.2988 5.7425 1.5347 0.1965
COR-L95 GDSC1; GDSC2 4.3121 5.7979 1.5203 0.2186
DMS 273 GDSC1; GDSC2 4.3179 6.5893 2.4249 2.9601
NCI-H1105 GDSC1; GDSC2 4.3332 5.6998 1.5616 0.1449
HCC33 GDSC2 4.3441 5.8492 1.5141 0.2209
NCI-H2291 GDSC1; GDSC2 4.3691 11.7749 -1.0818 12.745
NCI-H740 GDSC2 4.3976 7.1349 1.0487 1.7025
NCI-H1355 GDSC1; GDSC2; CCLE 4.4036 10.5181 0.5807 11.8238
NCI-H1299 GDSC1; GDSC2 4.4076 13.5506 -0.9182 19.219
NCI-H1373 CCLE 4.4162 6.235 2.3546 1.1808
RERF-LC-Sq1 GDSC1; GDSC2 4.4199 16.1276 -2.1905 23.7018
NCI-H526 GDSC1; GDSC2 4.4542 6.3643 2.6086 1.8521
NCI-H2081 GDSC1; GDSC2 4.5188 6.4975 1.3487 0.5351
Calu-6 GDSC1; GDSC2 4.5345 12.1752 -0.1393 15.6148
NCI-H1436 GDSC1; GDSC2 4.5565 6.1094 1.5007 0.1879
NCI-H1184 CCLE 4.5804 6.9919 2.1164 2.0043
NCI-H650 GDSC1; GDSC2; CCLE 4.5946 7.7891 2.039 4.231
RERF-LC-MS GDSC1; GDSC2; CCLE 4.6072 8.7894 1.3102 5.829
NCI-H2227 GDSC1; GDSC2 4.6141 6.1525 1.5064 0.166
HCC2935 CCLE 4.6515 11.2302 0.1668 11.3965
EMC-BAC-2 GDSC1; GDSC2 4.6702 15.478 -1.6723 21.4248
NCI-H1836 GDSC1; GDSC2 4.6815 6.3462 1.4639 0.2177
NCI-H1781 GDSC1; GDSC2 4.6977 6.481 2.6881 1.212
NCI-H2810 GDSC2 4.7162 7.3972 1.0901 1.255
NCI-H322 CCLE 4.7598 7.3777 2.0454 2.1042
NCI-H1648 GDSC2; CCLE 4.7678 12.7931 -0.2693 14.9436
NCI-H748 GDSC2 4.7744 6.4339 1.467 0.19
IST-SL1 GDSC1; GDSC2 4.8283 6.4934 1.4657 0.18
Ms-1 GDSC1; GDSC2 4.8725 6.9046 2.5982 1.4048
SW1573 GDSC1; GDSC2 4.9112 10.4991 0.956 9.5181
NCI-H1651 GDSC1; GDSC2; CCLE 4.919 8.6383 1.8476 4.6464
NCI-H1573 GDSC1; GDSC2; CCLE 4.9309 10.7135 0.866 9.4076
PC-14 GDSC1; GDSC2 4.9428 9.2319 1.584 6.2341
NCI-H2170 GDSC1; GDSC2; CCLE 4.9485 12.1388 0.1846 12.5696
SW1271 GDSC1; GDSC2; CCLE 4.9743 9.6092 1.4258 6.606
RERF-LC-A1 CCLE 4.9748 9.1597 1.369 4.9512
NCI-H1693 GDSC1; GDSC2; CCLE 5.0036 12.4145 0.0896 12.8894
RERF-LC-KJ GDSC1; GDSC2 5.0041 6.9269 2.6536 1.0584
DMS 53 GDSC1; GDSC2 5.0283 12.2635 0.1811 13.073
Lu-165 GDSC1; GDSC2 5.0354 6.3138 2.9035 0.2643
NCI-H2818 GDSC1; GDSC2 5.0444 18.4666 -2.8671 24.3406
NCI-H1963 GDSC2 5.0472 7.674 2.3598 2.2455
EKVX GDSC1; GDSC2 5.0621 10.8003 -0.1861 6.8903
T3M-10 CCLE 5.1317 10.3112 0.9316 6.8228
HCC366 GDSC1; GDSC2 5.1317 9.2853 0.5175 3.2937
LXF 289 GDSC1; GDSC2 5.1462 11.9644 0.4105 11.7471
NCI-H810 GDSC1; GDSC2; CCLE 5.1559 6.8724 2.744 0.596
NCI-H1581 GDSC1; GDSC2; CCLE 5.1847 12.3421 0.2542 11.7966
NCI-H2369 GDSC1; GDSC2 5.1874 7.7702 2.3927 1.9381
LK-2 GDSC1; GDSC2 5.1997 9.0597 1.8259 4.5861
NCI-H2141 GDSC1; GDSC2 5.2102 6.9404 2.7411 0.607
NCI-H1838 GDSC2 5.2766 7.246 2.6514 0.8499
Lu-99A GDSC1; GDSC2 5.2983 11.1334 0.9151 8.9876
HOP-62 GDSC1; GDSC2 5.3129 9.2914 1.788 4.6008
NCI-H1341 GDSC1; GDSC2; CCLE 5.3141 6.9235 2.7905 0.3906
NCI-H2023 GDSC1; GDSC2; CCLE 5.3264 12.6607 0.1992 11.7777
NCI-H1435 GDSC1; GDSC2 5.3296 6.9254 2.796 0.3932
Calu-3 GDSC1; GDSC2; CCLE 5.3821 8.0549 2.3718 1.7156
COR-L88 GDSC1; GDSC2 5.3935 7.5994 2.5642 1.0635
SK-MES-1 GDSC1; GDSC2 5.4172 14.5043 -0.6338 15.8659
NCI-H1694 GDSC1; GDSC2; CCLE 5.4201 6.8754 2.8491 0.2282
NCI-H2009 GDSC1; GDSC2; CCLE 5.4531 10.7069 1.2185 6.8127
NCI-H1915 GDSC1; GDSC2; CCLE 5.4559 14.0108 -0.3653 13.9849
NCI-H1792 GDSC1; GDSC2; CCLE 5.4664 15.2874 -0.9813 16.4388
NCI-H1650 GDSC1; GDSC2; CCLE 5.4669 9.0349 1.993 3.208
NCI-H1155 GDSC1; GDSC2 5.478 7.2847 2.7227 0.5108
NCI-H513 GDSC1; GDSC2 5.4795 15.91 -1.2771 18.2652
NCI-H522 GDSC1; GDSC2; CCLE 5.4802 7.9984 2.4435 1.3562
NCI-H1876 GDSC1; GDSC2 5.4968 6.962 2.8471 0.2222
HCC15 GDSC1; GDSC2; CCLE 5.515 8.4331 2.2798 1.9472
NCI-H1048 GDSC1; GDSC2; CCLE 5.5656 7.2743 2.7615 0.3532
NCI-H2731 GDSC1; GDSC2 5.6004 15.532 -1.0041 16.9802
NCI-H3255 GDSC1; GDSC2; CCLE 5.6016 8.2053 2.1144 1.074
NCI-H196 GDSC1; GDSC2 5.7 11.7745 0.8751 8.468
NCI-H23 GDSC1; GDSC2; CCLE 5.7046 7.5674 2.7092 0.414
LOU-NH91 GDSC1; GDSC2; CCLE 5.7053 8.4753 2.3563 1.4814
NCI-H1623 GDSC1; GDSC2 5.7055 11.0549 1.2153 6.8012
NCI-H1568 GDSC1; GDSC2; CCLE 5.7129 12.1623 0.7003 8.8095
HCC827 GDSC1; GDSC2 5.7344 14.3614 -0.3395 13.9956
NCI-H2066 GDSC1; GDSC2 5.7472 7.5789 2.7217 0.3921
NCI-H596 GDSC1; GDSC2 5.763 7.2276 2.8514 0.1497
NCI-H2085 GDSC1; GDSC2; CCLE 5.7638 9.5042 1.9504 3.0372
NCI-H1092 GDSC1; GDSC2; CCLE 5.7675 7.2895 2.8317 0.1671
SBC-5 GDSC1; GDSC2; CCLE 5.7708 12.2514 0.6959 8.7332
IA-LM GDSC1; GDSC2; CCLE 5.8576 13.0386 0.3796 10.0207
UMC-11 GDSC1; GDSC2 5.8681 16.5758 -1.3215 17.6499
NCI-H2087 GDSC1; GDSC2; CCLE 5.8695 14.038 -0.0904 12.0592
NCI-H1793 GDSC1; GDSC2; CCLE 5.9193 13.6423 0.1329 11.0058
COR-L105 GDSC1; GDSC2 5.9233 18.0092 -1.9827 19.852
NCI-H661 GDSC1; GDSC2; CCLE 5.9253 8.2434 2.5469 0.7175
NCI-H2342 GDSC1; GDSC2 5.9291 8.1304 2.591 0.6346
VMRC-LCD GDSC1; GDSC2; CCLE 5.9489 14.4373 -0.2281 12.5025
NCI-H1975 GDSC1; GDSC2; CCLE 6.008 15.8615 -0.875 15.0082
NCI-H2595 GDSC1; GDSC2 6.0106 8.2785 2.569 0.6521
NCI-H358 GDSC2; CCLE 6.0244 15.0122 -0.4531 13.3006
NCI-H1688 GDSC1; GDSC2 6.0263 8.1312 2.6298 0.49
LCLC-97TM1 GDSC1; GDSC2 6.1728 18.4437 -2.0148 19.4753
NCI-H1869 GDSC1; GDSC2; CCLE 6.2138 13.1151 0.5745 8.5682
NCI-H2405 GDSC1; GDSC2 6.2838 13.9451 0.2294 10.484
NCI-H441 GDSC1; GDSC2; CCLE 6.2858 15.8817 -0.6925 13.7991
HOP-92 GDSC1; GDSC2 6.3395 9.2171 2.3503 1.1041
PaCa-3 GDSC1; GDSC2 6.376 16.3071 -0.8354 14.828
NCI-H2373 GDSC1; GDSC2 6.5828 20.3846 -2.6681 20.7471
HCC78 GDSC1; GDSC2; CCLE 6.6548 15.3052 -0.1719 11.0739
NCI-H1755 GDSC1; GDSC2 6.6754 24.0808 -4.4126 25.0856
NCI-H1563 GDSC1; GDSC2; CCLE 6.8452 14.4094 0.3668 8.5149
NCI-H226 GDSC1; GDSC2; CCLE 7.0181 16.7571 -0.6215 12.2953
NCI-H1703 GDSC1; GDSC2 7.0834 25.7621 -4.9386 25.527
NCI-H2461 GDSC1; GDSC2 7.0852 21.6923 -2.9473 20.6591
NCI-H2347 GDSC1; GDSC2 7.2059 17.6134 -0.904 13.6432
NCI-H841 GDSC1; GDSC2 7.3168 16.9389 -0.5149 11.9338
NCI-H2591 GDSC1; GDSC2 7.9139 17.6756 -0.4848 10.8906
COR-L23 GDSC1; GDSC2; CCLE 7.9819 19.2305 -1.1651 12.8381
KNS-62 GDSC1; GDSC2 8.0191 21.2891 -2.1131 16.564
LC-1/sq GDSC1; GDSC2 8.086 21.6814 -2.2555 16.91
NCI-H1666 GDSC2; CCLE 8.1022 20.0671 -1.4809 13.7647
NCI-H2722 GDSC1; GDSC2 8.3017 22.4334 -2.4703 17.2341
NCI-H727 GDSC1; GDSC2; CCLE 8.64 20.5998 -1.3896 12.6716
⏷ Show the Full List of 204 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1; GDSC2 4.2696 6.7515 2.318 3.5943
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE-11 GDSC1; GDSC2 2.47 9.3624 -1.2972 18.4386
TE-15 GDSC1; GDSC2 2.6065 8.0205 -0.5209 13.9462
KYSE-150 GDSC1; GDSC2 2.6731 8.987 -0.0679 20.0625
T.T GDSC1; GDSC2 2.8116 8.4941 0.2992 17.9016
TE-10 GDSC1; GDSC2 3.0759 5.9477 0.8347 4.771
KYSE-510 GDSC1; GDSC2 3.1945 5.2809 1.2157 2.3835
OE19 GDSC1; GDSC2 3.6335 7.272 1.6002 8.8407
OE21 GDSC1; GDSC2; CCLE 3.9892 13.0939 -1.0197 19.7229
KYSE-30 CCLE 4.1381 5.977 2.3188 1.6424
TE-6 GDSC1; GDSC2 4.4337 7.7782 1.9384 5.2985
KYSE-140 GDSC1; GDSC2 4.5638 8.7673 1.5518 7.1008
KYSE-270 GDSC1; GDSC2 4.967 6.966 2.6196 1.2237
TE-1 GDSC1; GDSC2 5.1665 6.6601 2.8286 0.3866
TE-8 GDSC1; GDSC2 5.254 16.0546 -1.5147 19.6013
KYSE-410 GDSC1; GDSC2; CCLE 5.2917 9.8637 1.5107 5.6805
OE33 GDSC1; GDSC2; CCLE 5.374 15.4136 -1.1107 17.1121
TE-5 GDSC1; GDSC2 5.3778 11.8839 0.6094 10.339
KYSE-520 GDSC1; GDSC2; CCLE 5.5257 8.3024 2.3401 1.7016
KYSE-180 GDSC1; GDSC2 5.5349 10.5799 1.3296 6.5164
COLO 680N GDSC1; GDSC2 5.5741 9.4056 1.8887 3.745
TE-9 GDSC1; GDSC2; CCLE 5.7174 7.2081 2.8418 0.1636
KYSE-450 GDSC1; GDSC2 5.7573 12.7768 0.4377 10.4553
KYSE-70 GDSC1; GDSC2 5.7664 10.4392 1.5351 5.1561
TE-4 GDSC1; GDSC2 5.8687 12.9216 0.4425 10.2324
EC-GI-10 GDSC1; GDSC2 7.1772 20.4755 -2.2933 18.5422
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OVK18 GDSC1; GDSC2 1.4554 7.694 -1.3126 21.5988
A2780 GDSC1; GDSC2; CCLE 2.494 6.2605 1.1162 13.7815
ONCO-DG-1 CCLE 3.4099 6.0752 1.7892 5.6085
IGROV-1 GDSC1; GDSC2; CCLE 3.4488 11.9327 -0.8782 20.4631
DOV13 GDSC1; GDSC2; CCLE 3.4975 13.7617 -1.7523 23.5339
HEY A8 CCLE 3.5315 8.1885 0.8343 10.4195
OC 316 CCLE 3.5632 5.1859 2.3333 2.4284
OC 315 CCLE 3.635 5.2285 2.36 2.1695
OV56 GDSC1; GDSC2 3.8492 6.649 2.0747 5.7287
COV318 CCLE 4.0839 5.388 2.5427 0.7609
Caov-3 GDSC2 4.1415 5.6604 1.5054 0.3063
Caov-4 GDSC1; GDSC2 4.3435 7.5435 1.9899 5.1935
MCAS CCLE 4.387 6.312 2.3071 1.4051
TOV-112D GDSC1; GDSC2; CCLE 4.4496 14.7458 -1.4796 20.3909
OVTOKO GDSC1; GDSC2; CCLE 4.4691 12.7788 -0.4878 16.5051
TOV-21G GDSC1; GDSC2; CCLE 4.5511 10.1305 0.8798 10.0716
OVSAHO CCLE 4.6219 8.7995 1.3149 5.7809
JHOS-2 GDSC1; GDSC2; CCLE 4.7466 10.7701 0.4567 9.8166
OAW42 GDSC1; GDSC2 4.7558 6.6396 2.6507 1.3072
ES-2 GDSC1; GDSC2; CCLE 4.7885 11.978 0.1469 13.0603
OC 314 GDSC1; GDSC2; CCLE 4.8052 11.6575 0.3164 12.2504
OVISE GDSC1; GDSC2 4.9148 6.1916 2.9007 0.3218
COV504 CCLE 4.9239 7.6746 2.0044 2.0941
OVMANA CCLE 5.3078 6.6696 2.563 0.127
JHOS-4 GDSC1; GDSC2; CCLE 5.3136 6.9829 2.4555 0.3033
EFO-21 GDSC1; GDSC2; CCLE 5.3543 7.1831 2.7096 0.5803
OAW28 GDSC1; GDSC2 5.634 7.7416 2.6149 0.7307
OVCAR-8 GDSC1; GDSC2; CCLE 5.8444 9.0285 2.1956 1.9568
EFO-27 GDSC1; GDSC2; CCLE 5.9634 7.8164 2.403 0.2125
TYK-nu GDSC1; GDSC2; CCLE 5.9761 17.0513 -1.4762 17.2959
FU-OV-1 GDSC1; GDSC2; CCLE 5.9793 7.6328 2.7894 0.1815
OVCAR-5 GDSC1; GDSC2 6.004 21.8346 -3.8053 24.8837
OVCAR-3 GDSC1; GDSC2; CCLE 6.1279 7.9096 2.7472 0.2096
OVCAR-4 GDSC1; GDSC2; CCLE 6.1279 10.706 1.623 4.0111
Kuramochi GDSC1; GDSC2; CCLE 6.481 8.3807 2.7116 0.1846
RMG-I GDSC1; GDSC2 7.3417 20.9034 -2.3862 18.5488
OV-90 GDSC1; GDSC2; CCLE 7.6693 14.9797 0.5934 6.4561
OVKATE GDSC1; GDSC2 7.9036 18.3155 -0.7875 12.081
SK-OV-3 GDSC1; GDSC2; CCLE 9.1134 19.9699 -0.8143 10.0211
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PK-59 CCLE 3.5302 6.9056 1.4695 7.0589
L3.3 CCLE 4.0211 6.516 2.0027 3.3288
PSN1 GDSC1; GDSC2 4.3034 9.7494 0.8849 11.1462
PK-45H CCLE 4.4471 9.0212 1.0933 7.2043
QGP-1 GDSC1; GDSC2 4.5024 14.922 -2.5128 18.7518
MZ-PC-1 GDSC1; GDSC2 4.536 7.9156 1.6738 4.3953
PL4 GDSC1; GDSC2 4.9368 6.8113 2.6686 1.0606
KP-4 GDSC2; CCLE 4.998 13.3562 -0.3761 14.9283
PK-1 CCLE 5.0277 8.1343 1.8608 2.595
PL45 CCLE 5.0452 8.1281 1.873 2.5209
Panc 08.13 GDSC1; GDSC2 5.0909 7.8164 2.3214 2.3658
KP-1NL CCLE 5.1451 7.917 2.0153 1.8171
Panc 03.27 GDSC1; GDSC2; CCLE 5.163 8.9159 1.8696 4.1764
Capan-1 GDSC1; GDSC2 5.1677 11.0628 0.8608 9.5019
HuP-T3 GDSC1; GDSC2; CCLE 5.46 13.002 0.1271 11.8515
SU.86.86 GDSC2; CCLE 5.6287 6.8379 2.9363 0.069
KP-1N GDSC1; GDSC2; CCLE 5.6916 11.332 1.0774 7.0966
DAN-G GDSC1; GDSC2 5.9888 13.1527 0.4118 10.163
HuP-T4 GDSC1; GDSC2; CCLE 6.0124 14.9729 -0.4424 13.2784
Panc 10.05 GDSC1; GDSC2; CCLE 6.0428 12.4167 0.7927 7.8552
SUIT-2 GDSC1; GDSC2; CCLE 6.0842 13.2333 0.4358 9.3926
HPAF-II GDSC1; GDSC2 6.0991 8.7812 2.4147 1.058
SW1990 GDSC1; GDSC2; CCLE 6.1426 11.3313 1.3521 5.1835
PaTu 8988t GDSC1; GDSC2 6.2103 13.2172 0.5245 9.2621
Panc 02.03 GDSC1; GDSC2; CCLE 6.2135 16.5919 -1.0851 15.4363
KP-3 GDSC1; GDSC2; CCLE 6.3345 14.8261 -0.1547 11.5291
KP-2 GDSC1; GDSC2; CCLE 6.4767 15.6099 -0.4335 12.4373
HPAC GDSC1; GDSC2; CCLE 6.5673 16.38 -0.7406 13.5024
BxPC-3 GDSC1; GDSC2 6.6434 15.3351 -0.1934 11.719
Panc 04.03 GDSC1; GDSC2; CCLE 6.7104 14.3523 0.3099 8.9589
CFPAC-1 GDSC1; GDSC2 7.0959 18.2989 -1.3029 15.3234
Hs 766T GDSC1; GDSC2; CCLE 7.121 16.4291 -0.4007 11.2643
YAPC GDSC1; GDSC2 7.4618 16.1687 -0.0669 9.8746
PaTu 8902 GDSC1; GDSC2 7.5914 18.073 -0.8715 12.8896
AsPC-1 GDSC1; GDSC2; CCLE 7.8461 18.6946 -1.0006 12.4463
MIA PaCa-2 GDSC1; GDSC2; CCLE 7.9605 18.2062 -0.7013 11.1707
Capan-2 GDSC1; GDSC2; CCLE 8.1788 16.9621 -0.0018 8.187
⏷ Show the Full List of 37 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IST-Mes2 CCLE 0.8983 5.4478 -0.2303 23.3723
NCI-H28 GDSC1; GDSC2; CCLE 3.4336 11.0421 -0.4454 18.7244
MSTO-211H GDSC1; GDSC2; CCLE 4.1471 12.702 -0.6994 18.0926
MPP 89 GDSC1; GDSC2; CCLE 5.4892 11.4834 0.8753 8.3723
NCI-H2052 GDSC1; GDSC2; CCLE 5.9029 12.9097 0.4707 9.536
NCI-H2452 GDSC1; GDSC2; CCLE 6.2273 16.7307 -1.1427 15.626
IST-Mes1 GDSC1; GDSC2; CCLE 7.085 16.7338 -0.5671 11.9768
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H660 GDSC2 3.5275 5.4036 1.3397 1.3241
LNCaP clone FGC GDSC1; GDSC2 3.7259 13.5825 -1.4757 22.9689
22Rv1 GDSC1; GDSC2; CCLE 4.0409 11.3977 -0.1336 15.9262
VCaP GDSC1; GDSC2 5.1088 13.3244 -0.2796 14.9947
PC-3 GDSC1; GDSC2; CCLE 6.0293 8.0292 2.6681 0.3788
DU145 GDSC1; GDSC2; CCLE 6.1694 8.0187 2.7244 0.2348
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC1; GDSC2; CCLE 6.6002 8.0711 2.8554 0.0416
Cancer Drug Sensitivity Data Curated from 72 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
WM983B CCLE -0.3116 4.1521 -0.9833 31.2759
MZ-MEL-2 GDSC1; GDSC2 -0.0702 8.8347 -3.2657 34.4702
COLO 800 GDSC1; GDSC2 0.5016 10.385 -3.4985 33.0328
G-mel GDSC1; GDSC2 0.7453 7.128 -1.6723 25.7576
MDA-MB-435S CCLE 1.0921 4.699 0.2946 20.1845
Hs 895.T CCLE 1.7811 8.3364 -0.7416 25.9321
A-388 GDSC1; GDSC2 2.5107 8.0034 -0.5875 14.58
Hs 940.T GDSC1; GDSC2 2.5553 10.1422 -1.6181 19.735
451Lu GDSC1; GDSC2 2.6393 6.9187 0.051 10.5177
IGR-1 GDSC1; GDSC2 2.6544 3.6618 2.4789 6.7657
IPC-298 GDSC1; GDSC2; CCLE 2.7165 5.8369 1.3389 9.7281
HT-144 GDSC1; GDSC2; CCLE 3.1443 5.029 2.3162 5.7495
COLO 783 GDSC1; GDSC2 3.1728 10.1237 -1.1307 15.7372
MMAc-SF GDSC2 3.2447 5.4012 1.1906 2.4412
VMRC-MELG GDSC2 3.3355 5.1911 1.3319 1.5854
MZ-MEL-7 GDSC1; GDSC2 3.3526 6.339 0.8274 4.287
HMV-II GDSC2 3.4131 10.9597 -0.4213 19.6028
IGR-39 CCLE 3.6223 11.8619 -0.9236 18.5616
LOX-IMVI GDSC1; GDSC2; CCLE 3.6319 10.4559 0.0099 16.234
WM793 GDSC1; GDSC2; CCLE 3.732 9.8428 0.3966 14.1902
CP50-MEL-B GDSC1; GDSC2 3.798 10.4298 -0.8268 12.6884
HMCB CCLE 3.8208 7.2064 1.5354 6.108
WM1799 CCLE 3.8444 11.8798 -0.7573 17.3366
SK-MEL-28 GDSC2 3.8675 17.5785 -4.2929 25.9738
WM1552C GDSC1; GDSC2 3.9791 6.1764 2.3983 3.7002
A-431 GDSC1; GDSC2 4.0057 15.3134 -3.068 21.8943
Hs 936.T CCLE 4.0786 8.8918 0.8975 8.9167
WM88 CCLE 4.0961 9.3362 0.6925 9.9286
Malme-3M CCLE 4.1455 8.9543 0.9151 8.6917
Hs 938.T GDSC1; GDSC2; CCLE 4.1591 10.8354 0.0013 13.1993
RPMI-7951 GDSC1; GDSC2 4.1904 14.0517 -1.3374 21.3347
A2058 GDSC2; CCLE 4.239 5.4774 2.8785 0.8449
RVH-421 GDSC1; GDSC2; CCLE 4.2828 9.9917 0.5071 10.4777
Hs 852.T CCLE 4.3701 9.1093 0.9981 7.8313
SK-MEL-2 GDSC1; GDSC2; CCLE 4.4665 5.9345 2.8012 0.9255
Mel Ho GDSC1; GDSC2; CCLE 4.487 9.8131 0.739 8.9166
SK-MEL-30 GDSC2; CCLE 4.515 8.2923 1.4848 5.1104
K029AX CCLE 4.5929 10.9468 0.2632 11.0506
SK-MEL-31 GDSC1; GDSC2; CCLE 4.6043 6.6832 2.2611 1.3691
SF8657 CCLE 4.609 6.6167 2.2913 1.2448
COLO 679 GDSC1; GDSC2; CCLE 4.636 7.0991 2.3835 2.5275
GAK GDSC1; GDSC2 4.6513 8.6926 1.6474 6.4308
Hs 294T CCLE 4.6572 9.1947 1.1509 6.5401
Hs 944.T CCLE 4.7176 9.5829 1.0065 7.156
DJM-1 GDSC1; GDSC2 4.7427 14.9627 -2.3623 17.6487
WM278 GDSC2 4.8161 10.3783 0.9481 9.7461
CP66-MEL GDSC1; GDSC2 4.8462 16.1828 -2.8821 19.4007
G-361 GDSC1; GDSC2; CCLE 5.0665 13.5518 -0.4219 14.9831
SK-MEL-1 GDSC1; GDSC2 5.1022 9.0714 1.7606 5.0652
LB2518-MEL GDSC1; GDSC2 5.179 14.3466 -1.7673 14.2827
UACC-62 GDSC1; GDSC2 5.3968 10.9101 1.0864 7.9584
IGR-37 GDSC1; GDSC2; CCLE 5.4756 12.0849 0.5793 9.7738
SK-MEL-5 GDSC1; GDSC2; CCLE 5.4914 13.8802 -0.5298 12.9456
SH-4 GDSC1; GDSC2 5.5359 14.9176 -0.7504 16.1024
IST-MEL1 GDSC1; GDSC2 5.6381 9.1382 2.0418 2.9605
CHL-1 GDSC1; GDSC2; CCLE 5.6831 11.3164 1.0794 7.1006
WT2-iPS GDSC1; GDSC2; CCLE 5.699 10.4575 1.4866 5.1872
A-375 GDSC1; GDSC2; CCLE 5.7086 13.2548 0.1762 11.1846
A101D GDSC1; GDSC2 5.7353 14.6059 -0.4573 14.4949
COLO 829 GDSC2 5.8311 15.722 -0.9318 16.2395
Hs 695T CCLE 5.8486 10.3585 1.3359 3.9128
SK-MEL-3 GDSC1; GDSC2 5.8985 16.4591 -2.2958 15.1103
M14 GDSC1; GDSC2 5.9701 14.4774 -0.233 13.0889
WM35 GDSC1; GDSC2 6.1456 16.3914 -1.0354 16.0363
Mel JuSo GDSC1; GDSC2 6.6012 16.1008 -0.5846 13.4188
COLO 792 GDSC1; GDSC2 6.7212 16.2858 -0.5929 13.2429
LB373-MEL-D GDSC1; GDSC2 6.7569 16.8516 -1.9354 12.1753
UACC-257 GDSC1; GDSC2 7.2874 18.0473 -1.0562 14.0852
MeWo GDSC1; GDSC2; CCLE 7.3797 19.7919 -1.8261 16.0595
SK-MEL-24 GDSC2; CCLE 8.5426 19.7979 -1.0785 11.7228
WM115 GDSC1; GDSC2 11.2136 25.7009 -2.1759 12.3197
EquiPSC Line K2 GDSC1; GDSC2 5.3225 15.6596 -2.2985 16.2158
⏷ Show the Full List of 72 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1; GDSC2 1.0376 18.0821 -6.8565 37.7194
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE 617.T CCLE 1.7597 7.6862 -0.4429 21.5052
G-401 GDSC1; GDSC2; CCLE 2.1809 11.1896 -1.5991 26.4877
Hs 633.T GDSC1; GDSC2 2.7676 8.8112 0.1027 18.9832
RKN GDSC1; GDSC2; CCLE 3.0381 4.5652 2.4504 5.332
SW982 GDSC1; GDSC2 3.0686 11.7082 -1.0842 23.2433
KYM-1 GDSC2 3.3272 14.2978 -2.1616 26.2549
G-402 GDSC1; GDSC2 3.6874 17.3233 -3.3766 28.691
GCT GDSC1; GDSC2; CCLE 3.7247 9.8485 0.3879 14.2487
TE 441.T GDSC2 3.8142 5.1984 1.5459 0.3453
STS-0421 GDSC1; GDSC2 4.437 11.1355 -0.7313 10.8398
A-204 GDSC1; GDSC2; CCLE 4.4777 15.0879 -1.6278 21.7057
RD GDSC1; GDSC2; CCLE 4.8884 10.872 0.7593 10.0008
SK-LMS-1 GDSC1; GDSC2 5.0177 11.4801 0.5552 11.3043
VA-ES-BJ GDSC1; GDSC2 5.0328 16.2445 -1.7748 20.9814
EW-8 GDSC1; GDSC2 5.0529 6.7629 2.7415 0.7083
SW684 GDSC1; GDSC2 5.0579 6.3439 2.9013 0.2605
MFH-ino GDSC1; GDSC2 5.094 12.7207 0.0051 13.7509
HT-1080 GDSC1; GDSC2; CCLE 5.1905 7.0632 2.6849 0.7539
Rh41 GDSC2 5.4016 9.0479 1.9501 3.6891
MES-SA GDSC1; GDSC2; CCLE 6.0073 13.5624 0.2296 10.4318
SW872 GDSC1; GDSC2 6.0105 7.7479 2.7608 0.2299
Rh30 GDSC1; GDSC2; CCLE 6.0595 12.0525 0.9724 7.0144
SK-UT-1 GDSC2 6.1675 8.3145 2.6184 0.4583
Rh18 GDSC1 7.3113 23.9437 -4.9232 23.0561
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HSC-39 GDSC1; GDSC2 0.9036 5.6378 -0.1767 26.4961
HGC-27 GDSC1; GDSC2; CCLE 0.9787 5.8415 -0.1875 24.8525
KE-39 CCLE 2.4892 6.2755 0.9193 12.5902
SCH GDSC1; GDSC2 2.5885 4.3729 1.2609 3.2196
SNU-16 GDSC1; GDSC2; CCLE 3.0857 6.661 1.4516 10.4389
SNU-1 GDSC1; GDSC2; CCLE 3.1565 7.3718 1.1575 11.785
IM95 GDSC2; CCLE 3.1725 6.3728 1.6702 9.0741
AZ-521 CCLE 3.1747 8.2675 0.5104 12.9406
AGS GDSC1; GDSC2 3.3422 11.4417 -0.7211 21.0625
MKN45 GDSC2; CCLE 3.355 5.8229 2.0988 6.3693
SK-GT-2 GDSC1; GDSC2 3.491 6.6937 1.7748 8.219
KATO III GDSC1; GDSC2 3.7841 12.8244 -1.0498 21.2383
ECC12 GDSC2 3.7987 4.8829 1.6516 0.1276
MKN74 CCLE 3.9543 6.1575 2.128 2.8115
OCUM-1 GDSC1; GDSC2; CCLE 4.2008 10.3091 0.531 12.4926
SNU-5 GDSC1; GDSC2 4.5671 11.5424 0.1977 13.9792
TMK-1 GDSC1; GDSC2 4.6119 11.8462 -0.9535 11.6133
GCIY GDSC1; GDSC2; CCLE 4.7384 7.1529 2.4184 2.235
SH-10-TC CCLE 4.8076 5.9078 2.6462 0.1148
MKN1 GDSC2 5.1095 6.7958 2.7535 0.6318
ECC10 GDSC1; GDSC2 5.1334 11.8403 0.4616 11.5269
MKN7 GDSC1; GDSC2; CCLE 5.2731 7.1328 2.6941 0.6724
MKN28 GDSC1; GDSC2 5.3539 13.919 -0.3934 14.9822
NCI-N87 GDSC1; GDSC2; CCLE 5.5005 12.7547 0.2745 11.1192
Fu97 GDSC1; GDSC2 5.9013 20.7398 -3.342 23.9078
RF-48 GDSC1; GDSC2 6.0363 16.88 -1.3498 17.4263
NUGC-4 GDSC1; GDSC2; CCLE 6.2674 15.064 -0.3129 12.3003
RERF-GC-1B GDSC2; CCLE 6.2859 8.7703 2.4978 0.6632
TGBC11TKB GDSC1; GDSC2 6.4178 7.9876 2.822 0.0826
BGC-823 CCLE 6.5984 8.9701 2.2327 0.3248
23132/87 GDSC1; GDSC2 7.1041 18.2202 -1.2599 15.1518
NUGC-3 GDSC1; GDSC2; CCLE 7.3944 16.7267 -0.3668 10.714
Hs 746.T GDSC1; GDSC2; CCLE 8.4812 20.1735 -1.2906 12.5544
SNG-M GDSC1; GDSC2; CCLE 4.821 7.1137 2.4815 1.8597
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 17 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TT2609-C02 GDSC1; GDSC2; CCLE 2.7235 7.8286 0.5523 15.9753
8305C GDSC1; GDSC2; CCLE 3.4042 10.6674 -0.2825 18.0946
K5 GDSC2 3.8199 10.3126 0.2324 15.5528
BHT-101 GDSC1; GDSC2 3.8586 14.1952 -1.6742 23.3345
ML-1 [Human leukemia] GDSC2 4.227 6.0692 1.3899 0.5709
CAL-62 GDSC1; GDSC2 4.4437 8.765 1.4691 7.7763
IHH-4 GDSC1; GDSC2 4.5252 12.4188 -0.2668 16.2071
WRO GDSC1; GDSC2 4.6446 16.3298 -2.1153 22.9573
SW579 CCLE 4.7843 10.2106 0.7515 8.3019
KMH-2 GDSC1; GDSC2 4.8901 6.5756 1.4594 0.1759
HTC-C3 GDSC1; GDSC2 4.9654 11.3575 0.5777 11.2994
ASH-3 GDSC1; GDSC2 5.3545 10.0248 1.475 6.0886
B-CPAP GDSC1; GDSC2; CCLE 5.5245 12.2189 0.5481 9.8317
8505C GDSC1; GDSC2; CCLE 5.5327 10.3905 1.4162 5.7578
FTC-133 GDSC1; GDSC2 5.6399 7.0643 2.8636 0.1586
CGTH-W-1 GDSC1; GDSC2 5.9722 15.377 -0.6653 14.9004
TT GDSC1; GDSC2 6.8975 19.9872 -2.2517 18.9026
⏷ Show the Full List of 17 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PCI-38 GDSC1 -0.7963 3.5473 -1.5795 38.6142
JHU-011 GDSC1; GDSC2 -0.7506 6.67 -2.8929 36.2447
KOSC-2 GDSC1; GDSC2 -0.1268 5.1186 -1.5571 28.6966
PCI-04B GDSC1; GDSC2 -0.1244 6.2115 -2.061 30.7897
KON GDSC1; GDSC2 0.7725 13.2206 -4.6635 34.8794
BHY GDSC1; GDSC2 0.9159 5.2651 -0.6053 19.721
OSC-19 GDSC1; GDSC2 1.0139 8.0819 -1.8974 25.7791
BB30-HNC GDSC1; GDSC2 1.4732 9.4084 -2.1519 25.297
PCI-15A GDSC1; GDSC2 2.1992 6.2279 0.0496 11.7099
HSC-3 GDSC1; GDSC2 2.6237 10.5169 -0.8728 23.6768
PCI-06A GDSC1; GDSC2 2.6631 5.8903 0.576 7.2511
Hs 840.T CCLE 2.7103 7.1029 0.7024 13.1311
NCI-H3118 GDSC1; GDSC2 2.9726 12.3863 -1.5046 25.0442
HO-1-u-1 GDSC1; GDSC2 3.0009 10.324 -0.4501 20.8445
HO-1-N-1 GDSC1; GDSC2 3.1419 9.0806 0.2912 17.0196
PE/CA-PJ15 GDSC1; GDSC2 3.1619 6.6656 0.5501 6.286
Detroit 562 GDSC1; GDSC2; CCLE 3.5 7.545 1.3569 9.9168
BB49-HNC GDSC1; GDSC2 3.5102 19.7713 -4.7464 32.006
FaDu GDSC1; GDSC2; CCLE 3.5526 7.1031 1.62 8.4236
JHU-029 GDSC1; GDSC2 3.5593 12.4283 -1.9785 18.737
SCC-25 GDSC1; GDSC2; CCLE 3.7198 8.0974 1.0235 9.0125
SAS GDSC1; GDSC2 3.7684 12.6047 -0.9528 20.8979
BICR 31 GDSC2 4.349 6.0194 1.4559 0.3395
OSC-20 GDSC1; GDSC2 4.7176 9.8458 1.1372 8.971
SCC-9 GDSC1; GDSC2 5.02 8.2197 2.1017 3.4979
CAL-27 GDSC1; GDSC2; CCLE 5.0949 8.7998 1.8816 4.2191
PCI-30 GDSC1; GDSC2 5.1428 15.6441 -1.3953 19.4052
Ca9-22 GDSC1; GDSC2 5.2256 13.4824 -0.2724 14.7206
BICR 22 GDSC1; GDSC2 5.262 7.0751 2.7116 0.6652
HSC-4 GDSC2 5.3748 6.8166 2.8529 0.2491
BICR 10 GDSC1; GDSC2 5.5781 17.0112 -1.7455 19.7409
CAL-33 GDSC1; GDSC2 5.6202 13.4523 0.0206 12.6318
SAT [Human HNSCC] GDSC1; GDSC2 5.7111 16.1859 -1.2439 17.6729
SCC-4 GDSC1; GDSC2 5.7146 8.4805 2.3587 1.5533
DOK GDSC1; GDSC2 5.7483 18.343 -2.2749 21.1398
SCC-15 GDSC1; GDSC2 5.7811 7.7553 2.6705 0.4996
UPCI-SCC-090 GDSC1; GDSC2 5.7862 7.6555 2.7091 0.4051
LB771-HNC GDSC1; GDSC2 5.9082 9.3821 2.0791 2.4908
HSC-2 GDSC1; GDSC2; CCLE 6.3284 12.4945 0.9331 6.7958
BICR 78 GDSC1; GDSC2 6.7767 15.9631 -0.4035 12.3729
SKN-3 GDSC1; GDSC2 6.7797 16.3342 -0.5773 13.0786
JHU-022 GDSC1; GDSC2 7.349 19.8991 -1.8982 16.9666
⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BFTC-905 GDSC1; GDSC2 2.1534 8.3525 -0.2231 22.3521
JMSU-1 CCLE 2.9166 6.7868 1.0366 10.8267
T24 GDSC1; GDSC2; CCLE 3.0741 6.1371 1.4927 7.9822
SW780 GDSC1; GDSC2; CCLE 3.2642 10.6846 -0.4077 18.9872
KMBC-2 CCLE 3.6761 5.656 2.1844 2.9932
KU-19-19 GDSC1; GDSC2 3.7125 12.447 -0.9193 20.9062
TCCSUP GDSC1; GDSC2; CCLE 4.1203 7.0479 2.075 4.8742
HT-1197 GDSC1; GDSC2; CCLE 4.2609 5.8838 2.7131 1.5259
UM-UC-3 GDSC2; CCLE 4.7086 6.3492 2.7483 0.9052
639V GDSC1; GDSC2; CCLE 4.7592 10.2062 0.9916 9.1203
SW1710 GDSC1; GDSC2 5.2738 16.8728 -1.9036 20.9051
CAL-29 GDSC1; GDSC2 5.2857 7.1431 2.6956 0.7
647V GDSC1; GDSC2 5.3026 6.609 2.8993 0.185
J82 GDSC2; CCLE 5.3728 7.7978 2.4741 1.3366
5637 GDSC1; GDSC2; CCLE 5.6132 7.2304 2.7956 0.2676
HT-1376 GDSC1; GDSC2; CCLE 5.8469 8.2381 2.5154 0.8524
RT-112 GDSC1; GDSC2; CCLE 5.8965 15.2611 -0.662 14.3753
SCaBER CCLE 5.9666 13.2553 0.0836 9.42
RT-4 GDSC1; GDSC2; CCLE 6.4261 15.1486 -0.2475 11.7619
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW962 GDSC1; GDSC2 0.3586 11.6724 -4.2641 35.3458
SW954 GDSC1; GDSC2 0.9009 6.7755 -1.3559 23.7187
OVCA433 GDSC1; GDSC2 3.0057 9.5153 -0.956 15.2637
JAR GDSC1; GDSC2 3.1191 4.7738 1.3973 1.5413
CAL-39 GDSC1; GDSC2 3.1524 15.9684 -3.1432 29.4139
PA-1 GDSC1; GDSC2 3.2547 11.9499 -1.0482 22.6017
JEG-3 GDSC1; GDSC2 3.3321 5.0143 1.4049 1.2424
TC-YIK GDSC1; GDSC2 3.4118 5.2501 2.4316 4.7508
KGN GDSC1; GDSC2 3.6058 15.5176 -2.541 26.6804
C-33 A GDSC1; GDSC2 3.7806 5.8299 2.4267 3.9429
NT2-D1 GDSC1; GDSC2 3.8648 6.3082 2.2535 4.7144
BPH-1 GDSC1; GDSC2 3.9866 7.3684 1.8223 6.8174
OV17R GDSC1; GDSC2 4.049 8.542 0.238 6.3598
ACC-OV7 GDSC1; GDSC2 4.3323 8.6418 0.3626 5.1944
LB831-BLC GDSC1; GDSC2 4.4382 6.6558 2.4678 2.556
OVCA420 GDSC1; GDSC2 4.4904 8.4056 1.6757 6.586
OMC-1 [Human cervical carcinoma] GDSC1; GDSC2 4.6153 6.2673 1.4673 0.2293
HEY GDSC1; GDSC2 4.6259 13.8923 -0.9198 18.726
NCC-IT GDSC2 4.8752 9.9862 1.1786 8.4498
SW756 GDSC1; GDSC2 4.9301 7.3808 2.4242 2.0975
NEC8 GDSC1; GDSC2 5.0945 10.413 1.1227 8.3221
DSH1 GDSC1; GDSC2 5.1247 18.6611 -2.9019 24.2697
SKG-IIIa GDSC1; GDSC2 5.1757 6.7766 2.7888 0.488
JHOS-3 GDSC1; GDSC2 5.2092 7.0428 1.4127 0.1771
HeLa GDSC1; GDSC2 5.2731 12.3278 0.3232 11.9105
SiHa GDSC1; GDSC2 5.3246 6.6162 2.9048 0.1699
MS751 GDSC1; GDSC2 5.3427 6.7456 2.866 0.2339
Ca Ski GDSC1; GDSC2 5.3431 9.9184 1.5174 5.8953
HT-3 GDSC1; GDSC2 5.4006 6.8896 2.8366 0.2731
UWB1.289 GDSC1; GDSC2 5.4497 8.0883 1.1341 0.6628
PEO1 GDSC1; GDSC2 5.5398 16.8917 -1.715 19.714
C-4-I GDSC1; GDSC2 5.5534 7.2172 2.7774 0.3433
SKN GDSC1; GDSC2 5.657 17.6058 -1.9797 20.3712
HEC-1 GDSC1; GDSC2 5.7886 7.1837 2.8753 0.1144
ME-180 GDSC1; GDSC2 5.8296 10.6764 1.4647 5.4008
PWR-1E GDSC1; GDSC2 5.9757 7.9374 2.6805 0.3949
DoTc2 4510 GDSC1; GDSC2 6.1163 8.0744 2.6851 0.336
SiSo GDSC1; GDSC2 6.1167 7.7645 2.7931 0.158
OVMIU GDSC1; GDSC2 6.4912 13.1303 0.7398 7.8175
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Palbociclib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Talazoparib DM1KS78 Moderate Decreased clearance of Palbociclib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [12]
LY2835219 DM93VBZ Moderate Decreased metabolism of Palbociclib caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [13]
Tucatinib DMBESUA Major Decreased metabolism of Palbociclib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [14]
Coadministration of a Drug Treating the Disease Different from Palbociclib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Palbociclib caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [15]
Arn-509 DMT81LZ Major Increased metabolism of Palbociclib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [15]
Gilteritinib DMTI0ZO Moderate Decreased metabolism of Palbociclib caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [16]
Oliceridine DM6MDCF Moderate Decreased metabolism of Palbociclib caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [14]
Ivabradine DM0L594 Moderate Decreased metabolism of Palbociclib caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [16]
Troleandomycin DMUZNIG Major Decreased metabolism of Palbociclib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [14]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Palbociclib caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [15]
PF-04449913 DMSB068 Moderate Decreased metabolism of Palbociclib caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [17]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Palbociclib caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [16]
MK-8228 DMOB58Q Moderate Decreased metabolism of Palbociclib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [16]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Palbociclib caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [18]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Palbociclib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Tazemetostat DMWP1BH Moderate Increased metabolism of Palbociclib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [19]
Avapritinib DMK2GZX Moderate Decreased metabolism of Palbociclib caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [16]
MK-1439 DM215WE Minor Decreased metabolism of Palbociclib caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [20]
Berotralstat DMWA2DZ Major Decreased clearance of Palbociclib due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [21]
Pemigatinib DM819JF Moderate Decreased metabolism of Palbociclib caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [16]
Brigatinib DM7W94S Moderate Decreased metabolism of Palbociclib caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [15]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Palbociclib caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [22]
PF-06463922 DMKM7EW Moderate Increased metabolism of Palbociclib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [15]
Osimertinib DMRJLAT Moderate Decreased metabolism of Palbociclib caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [23]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Palbociclib caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [24]
Selpercatinib DMZR15V Moderate Decreased metabolism of Palbociclib caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [16]
GDC-0199 DMH0QKA Moderate Decreased metabolism of Palbociclib caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [15]
IPI-145 DMWA24P Moderate Decreased metabolism of Palbociclib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [25]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Palbociclib caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [26]
Arry-162 DM1P6FR Moderate Decreased clearance of Palbociclib due to the transporter inhibition by Arry-162. Melanoma [2C30] [15]
Selumetinib DMC7W6R Moderate Decreased metabolism of Palbociclib caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [27]
Ubrogepant DM749I3 Moderate Decreased metabolism of Palbociclib caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [28]
Rimegepant DMHOAUG Moderate Decreased clearance of Palbociclib due to the transporter inhibition by Rimegepant. Migraine [8A80] [29]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Palbociclib and Siponimod. Multiple sclerosis [8A40] [15]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Palbociclib and Ocrelizumab. Multiple sclerosis [8A40] [30]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Palbociclib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [16]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Palbociclib caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [16]
Abametapir DM2RX0I Moderate Decreased metabolism of Palbociclib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [31]
Lefamulin DME6G97 Moderate Decreased metabolism of Palbociclib caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [32]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Palbociclib when combined with Anthrax vaccine. Sepsis [1G40-1G41] [33]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Palbociclib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [16]
LDE225 DMM9F25 Moderate Decreased metabolism of Palbociclib caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [34]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Palbociclib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [16]
Larotrectinib DM26CQR Moderate Decreased clearance of Palbociclib due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [15]
LEE011 DMMX75K Moderate Decreased metabolism of Palbociclib caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [16]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Palbociclib due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [35]
Elagolix DMB2C0E Moderate Increased metabolism of Palbociclib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [15]
⏷ Show the Full List of 44 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Ammonia E00007 222 Alkalizing agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Palbociclib 100 mg capsule 100 mg Oral Capsule Oral
Palbociclib 125 mg capsule 125 mg Oral Capsule Oral
Palbociclib 75 mg capsule 75 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
2 ClinicalTrials.gov (NCT01723774) PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer. U.S. National Institutes of Health.
3 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
4 Dailymed: Terbutaline Sulfate Subcutaneous Injection
5 FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2015 Nov 1;21(21):4760-6. doi: 10.1158/1078-0432.CCR-15-1185. Epub 2015 Aug 31.
6 Clinical trials
7 Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther. 2015 Nov;355(2):264-71.
8 Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Feb;9(2):83-105.
9 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
10 Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
11 Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. 2017 Jul 4;8(27):43678-43691. doi: 10.18632/oncotarget.18435.
12 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
13 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
14 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
15 Cerner Multum, Inc. "Australian Product Information.".
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
18 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
19 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
20 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
21 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
22 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
23 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
24 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
25 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
26 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
27 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
28 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
29 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
30 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
31 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
32 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
33 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
34 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
35 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".